35 Burst results for "pharma r"

Parents Are Standing up Against Big Education and Critical Race Theory

The Dan Bongino Show

01:49 min | Last week

Parents Are Standing up Against Big Education and Critical Race Theory

"One of the things I talked about last night. Is the importance the primacy. Critical necessity of local action. How parents some of them for the first time when their kids were, you know, sent home doing their zoom classes with the coronavirus played there. They looked through their kids textbooks for the first time. And they said Wait. What the hell is this? I thought we were teaching our kids history, real history, battle scars and everything. Don't think we were teaching. Our kids had to be racist. But, ladies, gentlemen, that's what's happening. As critical race theory. You know, liberals will say there's no official critical race theory. No ladies and gentlemen, that's nonsense. It's an indoctrination process and they use euphemisms to get around it. That is exactly what's happening. We've seen some of the lectures in corporate America. We've heard on tape some of the attacks on our school kids. Critical race theory is racist, period full stop. There's no debate about that. And if you believe in critical race theory, as I've said repeatedly, it will say again. I'm sorry to tell you you're a racist too. Why am I bringing this up? Because people are getting intimidated at the, uh Very Very rewarding and enlightening fact that people are starting to act up. Starting to stand up. They've had enough they found out when and where their school board meetings are. And they don't like it. You know you have. What are the Liberals got? Big tech, Big Pharma. Big business, You know, it's interesting. They never talk about big education. Isn't a knock on teachers, but it is a knock on some corporate interests and others that make a whole lot of money off critical race theory. Critical race theory, activism classes wasn't really expensive textbooks.

America Big Pharma
A Test for Data-Driven Drug Development

The Bio Report

01:41 min | Last week

A Test for Data-Driven Drug Development

"Bill thanks for joining us daniel. Thanks for inviting me on the show. We're going to talk about smash avante. Its business model. And its efforts to better harness available data to speed drug development and improve decision making around it. perhaps we can begin with a little background. People may be familiar with the vikram swami's and his vance samanta was actually born out of sumitomo dainippon farmers acquisition of five vance. What is samat of antony. And where does it sit in relation to sumitomo in the group of vance acquired. Sure so as you mentioned was formed out of a three billion dollar transaction between a dainippon. Sumitomo pharma and raytheon Anytime a mid sized japanese pharma company. Roy vance is a startup pharmaceutical company about six six years old. So roy event has been successful at in licensing drugs in therapies refining their clinical development plan to optimize their positioning to address unmet need raising external capital to support the clinical development plan then hiring executive team to that clinical development plan so when a drug was expected to address high unmet need royden spun off a subsidiary to house. The drug generally named with the suffix van so dsp dainippon sumitomo purchased roy vance ownership stake in five of those subsidiaries and also to technology teams digital innovation headed by dan. Rothman and mike computational research team with our computational ecosystem that we burned of the drug

Vikram Swami Vance Samanta Sumitomo Dainippon Dainippon Sumitomo Pharma Roy Vance Sumitomo Vance Daniel Raytheon Bill Pharma ROY Rothman DAN Mike
Pharmas Image Gets a Boost from COVID-19

Medicare for All

02:26 min | 2 weeks ago

Pharmas Image Gets a Boost from COVID-19

"Two percent of people now have positive opinion of drug companies. And that's up from last year when it was only thirty two percent so we really gone of course. Public opinion is variable depending on. What's going on the news. And go down although i think that's quite largely but we've gone from this you know martin shkreli farmer burrow era to this apparently real rehabilitation of the pharmaceutical industries reputation through the cobra nineteen vaccine and case global saviors from this pandemic. So today. we're going to take a look at whether they actually deserve this. Newly found positive alert. I totally forgot about murmurs currently until just this moment. Thank you for reminding me of all that trauma so we have an amazing guests today. solo is a clinical pharmacy specialist at the university of chicago medicine. She's also co founders of pharmacists for single payer. Look shannon to the show inky you. Thanks for having me here. I'm really excited service. I'm just curious. How do as far aside you end up getting involved with the medical sheriff so bene- pharmacist for a little over ten years. I spent most of my earlier years working in inpatient settings where you really don't run into as many issues related to insurance or benefit manager as as the world so meaning that i worked in a hostile insurance hospitals every now and then this would come up. We'd want to discharge patients or child. They need an antibiotic wouldn't be covered in the nfc in hostels additional day while we tried to sort out how we can safely home for most of the time it was in you know you have the medications at our hospital wasn't much of a focus for me and then a few years ago i switch. You were primarily in using areas so not much community pharmacy but were in connects with physician and other care worker colleagues and in a specialty pharmacy role later. Working with really high cost drugs so think it was there that i started to encounter. How much of a barrier our system is in terms of getting by patients issues. Amy through that experience. I suppose is pretty fired up about that meets vans. You were involved in position for national health program and got more involved with that organization in an amnesty.

Martin Shkreli University Of Chicago Medicine Shannon NFC AMY
"pharma r" Discussed on Outcomes Rocket

Outcomes Rocket

07:42 min | 3 weeks ago

"pharma r" Discussed on Outcomes Rocket

"Insulin which also provided support to those who are going through job changes and potentially losing their jobs you to kobe there was. There's a lot there's still is and you know those who are eligible to receive insulin free of charge for ninety days. The our diabetes patients systems program. But we we really turns the shutdown which is a huge setback into a positive. Because we were able to keep everything going remotely because the company focused on employee safety first and ensuring the safety of our customers and making sure that they were going to get the medication that they needed regardless of this global shutdown. Yeah i i wasn't aware of the diabetes insulin program ninety days just just awesome and a testament to the power of focus right. I mean this dual focus because it could get complicated in times of challenge and when you hone it down to all right. We want our employees to be safe and we want our customers have access boom like get to it. It's possible exactly. Yeah i was very clear love it. And so amy how about you know. Let's do some horizon view in here. What are you most excited about. Well there's a lot personally right now. i'm just so excited that we have vaccines for covid. And it's springtime and i. It's been a tough year traumatic year in so many ways. I'm really excited about a spring thaw in the hope of some level of normalcy. Coming back for everybody. People have been through a lot but outside of that. You know i. I really think he about you. Know the pharmacies and life sciences. I love how it farm license. It's evolving from inside the organization to take action to garner new outcomes things like this. New organizational mindset in cultural shifts to better understand our customers as people. I did not patience and really focusing in on. Let's solve their problems and build from there and doing a lot of work at no votes to infuse these new ways of working these innovative mindsets cultural shift. That are gonna really help us. You sustain our current scientific model but then he get married science which is human and build for new opportunities into the future so for example you design thinking methodologies to uncover the customers problem to solve causes are indian commercial areas working together in discovery phase. No longer stilo two opposite ends of the development by site. Oh that's super exciting to be agile processes. We hear a lot about that. But using those to advance opportunity development work quickly so we can get the right interventions to our customers and really taking a really embedding that throughout the entire organization across all business units and really making it a muscle for the organization is going to be through these new ways of approaching understanding our customers that we can innovate solutions. That will improve. Those healthcare series is the quality of life. the outcomes synergistically with or beyond pharmacotherapy. So there's like this. Sort of underlying revolutionary field to all of it that is going to take us to the next level in healthcare. Yeah yeah it's it's the marge schott. I feel like we talk about moonshot that it's a marge schott and it's gonna happen. I agree and it's really about evolving evolving to your well care versus care you know the length. Scientists is always in many ways we are incentives are based on the stick care model and really really want to evolve to that welker model and make it a positive experience a not a frustrating experience. Totally super interesting amy. You know we. We've spent today talking about what could be and the the work that you and your team at novo are doing to make that reality happen. I'm confident it's going to happen. Thanks to efforts like yours and your teams and and the company and the leadership there. You know there's the other piece to that you know. We don't have time to talk about today. But you touched on his whole pharma value chain innovation and the opportunity. There is just a lot to be excited about. So i appreciate you sharing your vision and the work that you're doing before we conclude. I i love if you could just share closing thoughts with our listeners today and maybe share the best way that they could get in touch with you or find out some of the work that might be of interest to them at novo sure. Absolutely what's been great talking with you. I love this opportunity. And you as a closing thought something that comes to mind on a regular basis for me a few years ago i had the pleasure of attending the singularity university executive program. And you know for for those of you who are not familiar with singularity university into a global learning and innovation community using exponential technologies to tackle of the world's biggest challenges. And they have there's like twelve of them and build a better future for everyone that's what they're focused on. It was really super intensive week. Long mind-blowing program. And i'm telling you i still process it to this day. I think about it. I probably think about it at least once a week. Ever since i attended that but peter dumont the co founder and executive chairman said something that i really i used every day. He said the combination of the problem. Not the solution and in pharma. Were very hyper focused on getting our products in the hands of our customers to deliver your health benefit that we validated clinical trials. And we've secured the fda approval we we need to focus on hitting our numbers and achieving our share belief in all of those other metrics that are focused on our products. But they're not on our customers problems all the time. So this is a solution focused approach at it's limited in its success as evidenced by this rising the rising healthcare costs and you know the hearings rates in and the need to substantiate value in the real world setting won't be met with this traditional farm approach we've got to become emerging of our customers problems. What we've done to date has worked. It's worked well but it isn't working is not going to get us into the future. So now we have to really kind of focused on our customers problems to solve the hammered passionate about that and build a solutions anchored into that and put through. That's what i would like. You know just share with you guys become the problem not the solution and always happy to talk more. You can feel free to reach out to me. I like dimmed any west on legend. And i love talking about this stuff. It's so exciting. We're all trying to figure it out but we're going to have to figure it out together. We can't do it alone so so is opportunity. Amy thank you so much you said it so well and folks i wanna just have you reflect on this You thinking about your customers problems. Are you enamored with them. Because thinking about him is different than being enamored right amy. That's right difference if you're not. This is an opportunity for you to go beyond it and really just hit a home. Run with the efforts that you're striving for to improve outcomes and so just wanna give amy big. Thanks on behalf of all of us. Amy thank you and Certainly looking forward to stay in touch absolutely my pleasure. Thank you said about saw. It was really fun.

peter dumont Amy ninety days twelve today singularity university few years ago two university at least once a week novo them focus indian
"pharma r" Discussed on Outcomes Rocket

Outcomes Rocket

01:59 min | 3 weeks ago

"pharma r" Discussed on Outcomes Rocket

"Just want to welcome you to the podcast. Amy so glad you could join today. Thanks a lot saw. That was a great. I appreciate that introduction. Very much. And i'm really say to be here and get a chance to talk with you. Yeah likewise likewise. Amy and you know one of the things that we love to do is to sort of get to know the leaders so why and what inspires you to work in healthcare. Absolutely i would say that. I am personally very passionate about the patient side of healthcare because i am what i am a patient along with my and friends and i get it like we all have to engage in this healthcare ecosystem and i understand the benefits but also experienced the frustrations and i strongly believe that getting access to pharmacotherapy and traditional health. Interventions is critical but medication alone. It just isn't enough and sometimes it can be very hard to get tightly. Coordinated care you'll convenient access is a real challenge. I think that's only been exacerbated by the coded pandemic that we've seen but this is why i'm so excited to be working in the healthcare digital and tech space is i believe this is an area of innovation that can enable the ability to go beyond the pill or the proverbial pill and deliver experiences and create the convenient access. The positively influences patients understanding their behavior their engagement and the health decision making in a very personalized and relevant way and digital innovation gives us the opportunity to better understand patients as people i the human being and use technology to enable more individualized and relevant solution or support along with medication or the traditional interventions to achieve better quality of life overall improved outcomes. It's truly an exciting yet. Also challenging time to be working healthcare. But that's what inspires me.

Amy today eighty percent twenty percent both one nova nordisk two things
Pharma Value Chain Innovation with Amy West

Outcomes Rocket

02:00 min | 3 weeks ago

Pharma Value Chain Innovation with Amy West

"Just want to welcome you to the podcast. Amy so glad you could join today. Thanks a lot saw. That was a great. I appreciate that introduction. Very much. And i'm really say to be here and get a chance to talk with you. Yeah likewise likewise. Amy and you know one of the things that we love to do is to sort of get to know the leaders so why and what inspires you to work in healthcare. Absolutely i would say that. I am personally very passionate about the patient side of healthcare because i am what i am a patient along with my and friends and i get it like we all have to engage in this healthcare ecosystem and i understand the benefits but also experienced the frustrations and i strongly believe that getting access to pharmacotherapy and traditional health. Interventions is critical but medication alone. It just isn't enough and sometimes it can be very hard to get tightly. Coordinated care you'll convenient access is a real challenge. I think that's only been exacerbated by the coded pandemic that we've seen but this is why i'm so excited to be working in the healthcare digital and tech space is i believe this is an area of innovation that can enable the ability to go beyond the pill or the proverbial pill and deliver experiences and create the convenient access. The positively influences patients understanding their behavior their engagement and the health decision making in a very personalized and relevant way and digital innovation gives us the opportunity to better understand patients as people i the human being and use technology to enable more individualized and relevant solution or support along with medication or the traditional interventions to achieve better quality of life overall improved outcomes. It's truly an exciting yet. Also challenging time to be working healthcare. But that's what inspires me.

AMY
From Pharmacy Student to Clinical Scientist in Pharma with Dr. Anastasiya Koshkina

HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast

01:57 min | Last month

From Pharmacy Student to Clinical Scientist in Pharma with Dr. Anastasiya Koshkina

"Set you up for success so tell us a little bit about where you are in pharmacy school in terms of your career development. And what kind of activities and things that you partaking. That gave you the opportunity to do this polish. My in research Actually stemmed even before pharmacy school. And i came to pharmacy school with the thought that i do want to do. Research and i want to study drugs that point. I didn't really know and they didn't have a picture in my mind of how would happen. What is the best way to accomplish that. But i knew that i do want to go down. The research routes and not so much down the traditional pharmacists path rally although throughout pharmacy school. I definitely enjoyed All the clinical knowledge that we got and certainly the patient interactions that were exposed to and taught So that definitely is still with me. Even though i don't necessarily use it from day to day and so the realization that i wanted to come to industry really came from that question. Okay and one to study drugs. I how do i get it. How how. what does that pathway. That would definitely to to do research. And what should that. Research look like and throughout the pharmacy school of most intrigued. Me is the behind the scenes. The papers behind literature behind trials. I was always curious how it happened. That the paper was published. What kind of trial had to happen. What are all those stuff. What does it take to set up a clinical trial in order to result in this publication and then ultimately and improvement in treatments right and then it may the make into the guidelines. And and how does that process actually happened

Pharmacy School
A Diagnostics Company Moves to Developing Precision Cancer Therapies

The Bio Report

02:22 min | Last month

A Diagnostics Company Moves to Developing Precision Cancer Therapies

"Osama. Thanks for joining us. Thank you for having me danny. We're going to talk about four bio therapeutics. Its strategic shift from diagnostics to therapy dixon. Our seeking to build a pipeline of targeted therapies. Perhaps we can start with a little history though. Four was known as novellus deacs until this year. What was the name. Change meant to signal once again. Thanks for having me so let me let me maybe go back a little bit in time to come back to the present As you mentioned. Four prior to a few months ago was novellas novellas diagnostics company based out of jerusalem israel companies. About nine years old. It did start out as a diagnostic company The foundational product here was a functional genomics platform that helped physicians providers and pharma companies. Identify the right drugs for the right patients by looking at very specific molecular profiling by patient Over the years as the company was evolving in that diagnostic business model I think a combination of prior management and the board realized that there was a there was quite a bit of opportunity to think about diagnostics internally and develop diagnostics on their own because we were identifying unaddressed. Patient populations and matching them to therapies That were either being developed or already in the marketplace and so at believe early two thousand nineteen the board and the management team decided to pivot from a diagnostic business vital to therapeutics business model and leveraging the platform started to identify across a number of validated cancer targets unaddressed. Patient populations where there's a high unmet need and where the company could really help bring beneficial therapies to market under this scope in early twenty twenty the company in licenses its product from lexicon. It's a next generation. Be rafted addresses class one and class two mutations And within that again using the platform we have begged clearview into creative trial designs. That target high unmet need populations. These are commercially viable populations

Novellus Osama Dixon Danny Pharma Jerusalem Israel Cancer
Apple Commits $430 Billion in U.S. Investments Over Five Years

Morning Edition

01:01 min | 2 months ago

Apple Commits $430 Billion in U.S. Investments Over Five Years

"Tech giant Apple announced this morning plans to invest more than $430 billion and add 20,000 new jobs across the country over the next five years from member station W. U. N. C. Jason to brew in reports on what that investment will look like. In North Carolina. Almost 3000 jobs will come to research Triangle Park commonly called RTP the tech and form a hob near Rollie. Those jobs will focus primarily on machine learning artificial intelligence and software engineering. Apple plans to build a one million square foot innovation hub in RTP for a total investment of more than a billion dollars. The area is surrounded by Duke UNC Chapel Hill, North Carolina state, seen by many tech and pharma companies as a rich talent pool, the Republican led North Carolina Legislature in 2016 past the infamous bathroom bill, which led progressive companies to curtail investment in the state. Law was fully repealed last year, and LGBT Q rights advocates credit the repeal for helping to attract the Apple investment.

W. U. N. C. Jason Apple North Carolina Triangle Park Duke Unc Chapel Hill Republican Led North Carolina
Patrick Radden Keefe on Empire of Pain

The Book Review

02:23 min | 2 months ago

Patrick Radden Keefe on Empire of Pain

"Patron kief joins us now. His new book is called empire of pain. the secret history of the sackler dynasty. Patrick thanks for being here. Thanks so much for having me back. So let's start with a very basic question. In case people are not aware of the sackler family and why he would be writing about them with title like empire of pain. who are the sackler. So this sort of to waste answer that question until a few years ago what. The sackler name Generally to to the extent that people were aware of this family it was a very wealthy family. One of the wealthiest families in the united states with a branch in the uk in london and they were known chiefly for philanthropy right art museum wings. Hundreds of millions of dollars to art museums and universities and medical research and would very often put their name on these bequests. If you you know in new york city go to the metropolitan museum of art and there's the sackler wing And that was what they were known for. What was more mysterious. Was the source of this wealth and it has People have become more widely aware. Recently that That the bulk of this wealth comes from a company purdue pharma which produces the powerful painkiller oxycontin in this era in which the naming of things and the un naming of things mounting and the on mounting has become very active. Is it still the circle ring. In the metropolitan museum is sackler still emblazoned on all of these buildings and donated wings. Well it's very much in flux. So as i speak today it's still the sackler wing but the has actually announced today initially. They said they weren't taking any future. Donations from the soccer is because of the connection between the family and the crisis and then more recently. They've said that they are You know i think assessing is is the word whether or not the sackler wing will remain the sackler wing. Some institutions have started to take the name down so tufts university took down the sackler name from a series of buildings Because the students there this is at the medical school had said. I don't wanna go to class in a building named after this family and and get my medical education. They're more recently. New york university has done the same. The louvre in paris is taken down the sackler name. So there's a real question for many of these other institutions and there's dozens and dozens of them were the name still stands whether or not they'll keep it

Patron Kief Joins Metropolitan Museum Patrick Pharma New York City London United States UK UN Soccer Tufts University New York University Paris
EU to Negotiate Major Vaccine Contract Extension With Pfizer

AP News Radio

00:49 sec | 2 months ago

EU to Negotiate Major Vaccine Contract Extension With Pfizer

"The European Union has thrown its considerable weight behind vaccine developer FISA by on tech and new technology it was amounts to a stinging rebuke the pharma giant AstraZeneca the head of the E. U.'s executive arm has announced plans for a major contract extension nineteen vaccines with Bonita stretching to twenty twenty three European Commission president us you to bond the lane says the block will started negotiating to buy one point eight billion devices through the next two years the lane adds the E. you need to focus on technologies that have proven their worth she also announced the FISA brown took we provide the E. U. with an extra fifty million doses in the second quarter of this year making up for the faltering deliveries of AstraZeneca I'm Charles the last month

European Union Fisa Astrazeneca Pharma Bonita European Commission Fisa Brown Charles
Philadelphia's Suburban Battleground: Can The GOP Recover?

Morning Edition

02:10 min | 2 months ago

Philadelphia's Suburban Battleground: Can The GOP Recover?

"Reliably voted Republican. But the suburbs have changed. And last November, Donald Trump lost them in a big way. Now, with the 2020 midterms in view, both parties are wondering what's going to happen when Trump is not on the ballot. NPR national political correspondent Don Gonyea reports from the vote rich Philadelphia suburbs. Leads drop in on Chester County, Pennsylvania, It's suburban Philadelphia but a place with its own identity. We have a huge agricultural community. We are the mushroom capital of the world. You could come here for a mushroom festival on New Year's Eve. It's quite fun Democrat Mary in Moscow It's his chair of the Chester County Board of Commissioners. And we have a lot of industry were very big in the bio Pharma life sciences community. We have new technology coming in. So ah, lot of great things happening here. Right Next door is Montgomery County, where lives create? Hey V chairs the local Republican party, she says she's watched these suburbs flip from red to blue some only in the past few years. But she says the shift began long before that, If you look at the trends, this has been happening for many, many years. I think it accelerated over the last couple of years. But when I moved into Montgomery County 21 years ago, it was already starting to change in 2016. Hillary Clinton beat Trump in these suburbs, but not by enough of a margin to make up for trump strength in the States rural areas. She lost Pennsylvania, but Joe Biden racked up huge margins in the Philly suburbs. It was key To his statewide victory. The suburbs are far more diverse than they were decades ago, and many suburban voters had an intense dislike of Donald Trump Republican create A V is hoping some of those more moderate voters come back to the GOP. Now that they don't have trump who people voted against because they didn't Like him as a person. He's gone now. And so people are actually looking at issues now and things that affect them on a day to day basis. The changing politics in the suburbs

Don Gonyea Chester County Board Of Commis Philadelphia Donald Trump Montgomery County Chester County NPR Pennsylvania Republican Party Moscow Mary Hillary Clinton Joe Biden Philly
Interview With Arnaub Chatterjee, Senior Vice President At Acorn AI

Outcomes Rocket

02:16 min | 3 months ago

Interview With Arnaub Chatterjee, Senior Vice President At Acorn AI

"Thanks so much for joining us. Yeah thanks for the opportunity. Great to be with you. Yes so talk to us a little bit about about you or not. What is it about health care that inspires you to stay focused on the field shirt. So i guess if i start off on a personal note i would say that medicine and health care are very much embedded in my in my dna. I come from a line of physicians that spans multiple generations and grew up with these stories of different patient encounters. Different clinical settings. So everyone my grandfather. My father my sister. My brother-in-law are all either physician or health services. Researchers are both could imagine that are thanksgiving discussion. They're pretty much heated. You know conversation over the state of health policy. Today you know type of my family. I had the opportunity to see across the healthcare system in in various roles over the last ten twelve years now and and kind of had a bite in in consulting in pharma in the government space in academia and. I think the thing that that keeps me going is that have been fortunate to be part of you. Know what. I what. I call these. The health dare movement and be they're gonna pivotal changes or sort of tectonic shifts in our healthcare system. I'm gonna happen within the last decade and kind of fundamentally transform the industry but also kind of thinking about how the healthcare system as a whole as evolving so some of the stuff that you you mentioned in my bio whether it was working on the affordable care act which was such a you know important piece of legislation or being part of of some of these larger data and technology movements even through the lens of the government big things that happened over the last several years and then more recently you know when i was at merck I had a chance to better understand what's commonly called. now it's real world data. Which is everything happening. Outside of data and clinical trials. And could that tie into improving economics research within that company. And i guess my most recent inflate of experiences are really pushing towards. How do you to move the needle in pharma research and development. And how do you better understand. Where data science and technology intersect with that changing space. So the the totality of everything. If you think about how interconnected the system is having those experiences. I have kind of shaped You know my my thinking now and really to where we are today. So that's been fun intents and kind of an inspirational experience to date for me. And i'm excited to continue development.

Pharma Academia Merck
How To Work Through Pregnancy And Menopause.

Women's Health By Heather Hirsch

05:44 min | 3 months ago

How To Work Through Pregnancy And Menopause.

"Hi and welcome to help each other hurt a podcast dedicated to uncovering many of the women's health issues many of us are wondering about but few of us are talking about my mission is to expose the current gaps in knowledge and Care on all things Women's Health. Enjoy. Welcome back to the show. So today's episode is going to be all about pregnancy and how conditions may may have affected your pregnancy can come back to play a role in perimenopause and menopause. So you may think these two are completely unrelated and I am here to let you know. There's actually some really interesting themes that we may be able to gleam from our pregnancy that we can use when we look forward to or as we're entering into perimenopause and menopause. Before we get into that let's hear a word from our sponsor from Pharma. Thank you so much for sponsoring. Today's episode film Pharma is a woman's health care company the focuses on putting women first off then Farm was established to help women who are often forgotten about the pharmaceutical industry their products address vaginal and Volvo dryness itching and pain. We're always told how important it is to moisturize our face, but our intimate areas just as important many women have trouble talking about dryness with their doctors and do not know where to turn them far. My mom is here for you. This company feels women should feel comfortable making intimate skin hydration a part of their daily skincare routine try their products today for relief from vaginal and Volvo, dryness wage and pain check them out at fem pharma.com. That's, you are not going to be disappointed. All right, so here comes a fun job. Moment of Truth one of the reasons I wanted to do this episode today is because I am expecting and I've been hiding this fact for a pretty long time. I am in my third trimester and so far pregnancy has gone just fine. I'm not one of those people who really enjoys being a pregnant. I know many women who do simply not one of them. So I have been trying to hide it and I guess that's my way of not focusing so much on it. Thankfully. I'm lucky to be pretty healthy during this pregnancy. And this will be my third child is a surprise. We don't know yet if it's going to be a boy or a girl so it'd be really fun if you want to stick around and see I'm due in early June and not anything like my last baby. This baby might be a little early. So if there is a little break in podcast episodes, it's probably because I just had a baby now you also log I love working and I love what I do is I'll probably be back pretty quickly. And at this point I've gotten really efficient at getting podcast episode out to you. So I wanted to let you know because I do not feel like I was being honest hiding this any longer and I am really excited but it really led me to think about let's talk about how pregnancy relates to. Pause and menopause now. I just said I'm one of those people who loves being pregnant. That's mostly because I'm uncomfortable a lot. However, I have been really blessed to have healthy pregnancies, but every single pregnancy can be thought of as a stress test. So do you know what a stress test is if you don't we typically think about cardiovascular stress tests where they put the little leads you and you have to walk or run on the treadmill and they're looking at the EKG to see when you're under stress what happens to your body and this is gleaming information about future cardiovascular or current call log. Vascular risks that you may have and pregnancy is a very similar. It's a, you know, forty weeks stress test to see when we put your body under a little bit of stress or conditions that arise that may play a role in your health as we go down the line and we're starting to clean so much more information about what we can take from our state and as pregnant women into our health as we go forward, for example, if you had gestational diabetes or gestational hypertension preeclampsia, a preterm birth postpartum depression off or any of these other complications, and I'm going to talk to you about what all those could mean and we're still Gathering a lot of this data. So more and more is to come now what you've never had a baby or you haven't had a pregnancy in your lifetime. I think this episode will still be really interesting because we're learning so much about maternal health and female birth. Factors that are completely independent or different from the traditional and I'm saying those are question. You can't see me risk factors, which is based on the mail system. So thinking about these is also really interesting as well as if you have a friend or a daughter or a niece who's going to be pregnant. This is such a really interesting information to know about first. I'm going to walk you through some soft findings and soft findings means. This is just what I see clinically and I don't really know how it's going to go on to apply but one of the things that I do see a very common basis is women who have had a postpartum depression seemed to have an increased risk for either pmdd, which is severe PMS or mood symptoms in perimenopause and into

Pharma Volvo Farm Gestational Hypertension Preec Preterm Birth Postpartum Depre Gestational Diabetes Postpartum Depression
Nevada announces $45M settlement with McKinsey over opioids

AP News Radio

00:41 sec | 3 months ago

Nevada announces $45M settlement with McKinsey over opioids

"Hi Mike Rossi a reporting the vada reaches a settlement with the firm tied to the opioid crisis after electing not to be party to a multi state settlement the vada has struck a deal with global consulting firm McKinsey and company for its role in helping Purdue pharma increased sales of prescription pain killers during the national opioid crisis McKinsey and company has agreed to pay the VAT up forty five million dollars in February the New York based company settled for five hundred seventy three million dollars with forty seven states the district of Columbia and five U. S. territories according to state Attorney General Aaron Ford had Nevada been party to the multi state deal it would have received seven million dollars hi Mike Rossi

Mike Rossi National Opioid Crisis Mckinse Vada Purdue Pharma Mckinsey Attorney General Aaron Ford New York Columbia Nevada
All About Crane's Critter Care

Say What Needs Saying

06:47 min | 3 months ago

All About Crane's Critter Care

"We are back we are doing a new segment where we bring on a small business owner so we can talk a little bit about their business about what they do. What kind of issues or problems. They've come up. Come against in starting in running a business. You know maybe business during kobe and whatever comes up and so right now we have with us gen from cranes critter care john. Thanks for joining us for the first small business segment. Thank you so much for inviting us into i actually chow four chinchilla friends with me this ursula one thing. That's a little bit different about further care. Is we go far beyond just captain dogs. We do all sorts of exotic whether it's earned small mammals sarmiento reptiles anything because we have so many people that have pets chats dogs in. I noticed when i was working at the ap l. That was a big issue. People were having was not being For anything other than just basing cat dog or if they had animal what medical issues. So that's one thing that Critter cares able to do is we can do animals with medical issues whether that be needing shots multiple times a day medications multiple times a day. We can do dogs or cats with behavioral issues. That could normally go to a kennel or normal. Dog sitter whether it be sonic stranger danger or anything bats. We also work with harder cheeses. I personally love the challenges in house. Seven years experience were sheltered in animals because training shelter. Animal is so much different than training in that. You thought from the pet store in today's nickel company though. It's just a little bit different methods of going about things but it's been really great overall. We've had to change a lot of cova right. And that's one thing. This kind of bennett trick is as cova comes up each month. We have to kind of a daft. Do whatever we see that customers are looking for whether if the people going out of town so that increase number of training sessions of we noticed people wanting more medical care people wanting more educational seminars. So whatever people are looking for cranes critter cares filling in that gap and just go with the flow of were covance. Add in what people are meeting with as far as animal care. So where would you say you start. Sounds like such an amazing and valiant effort that you're doing especially for individuals in the community. You're almost like an immeasurable acid because through You're still trying to push still trying to make sure that the animal care is first and foremost so what pushed you into his avenue this world so i actually started adding animal shelter as a veterinarian assistant. I was there for four years and then i switched to another shelter as their main foster four nader doing educational seminars. And that's one of the biggest issues i noticed was i was in the intake department where people would surrender. Animals in have issues in a big thing is lack of education whether it be their animal has issued. They don't know how to properly train or fix it. So then immediately playbay. Just surrender or their four hours a day. Don't have anyone to let them out in the they don't have time to have an animal or someone passed away or moved out there. Sheila left behind. They have no idea how to take care of. It can shallow surrender over and it's one of those things where the more education were able to provide the public a lot. More people keep animals in their homes. Take better care of their animals. It makes a better relationship between the owner of pet in more animals. Just stay healthy happy home. So it's a little bit of keeping animals out of the shelter keeping almond good conditions just for improve quality of life for everyone right. Yeah no so. I wanted to actually ask about something along those same lines. Since we've been going through cova. This is something that we touched on. In in one of my classes actually we were talking about Pharmaceuticals and medications for animals versus for people Was he was business of biology through. You're talking about big pharma quite a bit but you know one of the things that came up is that there's different right if you have a life threatening disease or disorder. You're probably more likely to get that medication than you would. For a life threatening disease or disorder for an animal or at least some people are so along those same lines of what you were talking about. One thing that i was hoping to kind of get out there. One thing i think that needs saying is i'm sure that lots of people bought a new animal because the kobe right. You're locked up. You're stuck at home. You need a buddy someone. Yeah but that said tat. I'm slightly concerned that we're gonna see a big christmas dump ejup fact at the end of covid right where everyone is like. Well now. we're back at work now. We're back at school now. We're busy now. We don't have any time and so well. We have to get rid of the animals. So i guess i wanted to kick it over to jenin. Just see what you thought about that. Do you think that phenomenon is going to happen once we quote unquote get back to normal and like what could you say to pet owners. That currently do have their pet that you know maybe thinking of doing something like that so i completely agree and that's something even when i felt the shelter we talked about with so many people now that they're working from home temporarily were adopting animals but they're not thinking in the future a lot of those times so that's one thing during summer especially i focused on was doing seminars in different on how to prevent separation anxiety. That's gonna be one of the issues as well with on people getting poppies. The puppies are missing to people being home all day leaving for maybe two hours tops and all of a sudden you're drastically or changing their schedule their way of life pretty much by being gone nine ten hours a day. That's going to have a lot of issues with separation. Anxiety being the biggest one and then i see a lot of people once that happens to run around to shelters reasonable surrender.

Cova AP Bennett John Sheila Jenin
Purdue Pharma Offers Restructuring Plan, Sackler Family Would Give Up Ownership

News and Perspective with Tom Hutyler

00:36 sec | 3 months ago

Purdue Pharma Offers Restructuring Plan, Sackler Family Would Give Up Ownership

"Do Pharma submitting its bankruptcy restructuring plan overnight? Here's compost Frank Lindsay. The Sackler family owns the company. They boosted their offer to settle opioid lawsuits to $4.28 billion. That's 1.3 billion Maura than their original offer. Produce farm a file the bankruptcy restructuring plan right before the midnight deadline. Money from the settlement deal will go to reimburse states, local governments and other plaintiffs who super due for its role in the opioid crisis. Last month, Washington State Attorney General Bob Ferguson announced our state share would be $13.5 Million, which will go toward treatment prevention and other efforts to fight the opioid

Frank Lindsay Pharma Maura Washington State Attorney Bob Ferguson
Purdue Pharma proposes $10 billion plan to come out of bankruptcy

Morning Edition

03:45 min | 3 months ago

Purdue Pharma proposes $10 billion plan to come out of bankruptcy

"Pharma, The company that makes OxyContin filed its bankruptcy plan last night, And here is the plan, the company itself will be dissolved. A new organization will be created that will direct profits to help people. Hurt by the opioid epidemic. Now, two dozen states immediately rejected this plan to help answer why NPR's addiction correspondent Brian Mann is with us. Hi, Brian. Hey. Good morning, Noel. How did Purdue Pharma described this plan working overtime. Yes. So what the company's president Steve Miller says, is that a new company is going to be created from the ashes of produce farmer that's going to essentially exist to benefit the public. The sack lawyers will have no roller ownership. And over time, this new firm will generate hundreds of millions of dollars, much of it from selling OxyContin, which they say they can do ethically and safely. Will also produce medicines that will go to help people suffering from opioid addiction, and they saved a total value of all that overtime will be roughly $10 billion. Members of the Sackler family also issued a statement late last night, saying, this plan offers and I'm quoting here. An important step toward providing help to those who suffer from addiction. It was clearly thought through. Why did so many states come out and rejected? Offhand? Yeah, there were months of negotiations leading up to this and a big complaint from state attorneys general, most of them Democrats, Noel is that produce farmer and its owners. Seculars. They're gonna only offer of about $500 million, right. At first. The rest of the cash payments, including $4.2 billion promised by the Sackler is themselves. That would be spread out slowly in installments that would be paid over most of the next decade. And that slow pace really angers critics like Maura Healey, she's attorney general in Massachusetts. What the sacristy are offering essentially is a way for the payments to be structured. That makes it convenient for them. They get to keep their billions of bank accounts and make money and use the interest to pay. You know, the state's out over time. Well there OxyContin fortune keeps growing. And there's one other rub here for critics, and that's the fact that a lot of that $10 billion in value that produce farmer talks about it doesn't actually come in the form of cash, which communities really need to pay for addiction programs. And said the plan envisions providing low cost addiction treatment drugs like people, Morphine and the lock zone, which this new spinoff company they hope to create, would make and sell at a discount.

Brian Mann Sackler Noel Purdue Pharma Oxycontin Steve Miller Pharma NPR Maura Healey Brian Massachusetts
Purdue Pharma proposes $10 billion plan to come out of bankruptcy

Up First

03:25 min | 3 months ago

Purdue Pharma proposes $10 billion plan to come out of bankruptcy

"Pharma the maker of oxycontin filed. Its long bankruptcy plan just before midnight last night in a federal court right. So here's the plan. The company itself will be dissolved. A new organization will be created that would direct profits to help people who were hurt by the opioid epidemic but two dozen states came right out and they rejected that plan. They say it doesn't hold the sackler family which owns purdue pharma accountable. Let's bring bringing. Npr's addiction correspondent. Brian man Brian what does purdue pharma savings. This plan will do the company's president a he's a guy named steve miller and he says this new company that will be created from the ashes of purdue farmable essentially exist to benefit the public. The sackler will have no role or ownership going forward and over time. This new firm will generate hundreds of millions of dollars much of it from selling oxycontin which they say they can do ethically and safely. They'll also produce other medicines that will help people with opioid addiction. According to purdue pharma the total value over time To thousands of creditors will be billions of dollars and members of the sackler family also issued a statement last night. They said this plan offers. And i'm quoting here. An important step forward helping those who suffer from addiction. Okay but wire so many states unhappy about this a lot of reasons but a big complaint is from state attorney general most of them democrats who say that purdue pharma and its owners the sackler only offering up about five hundred million dollars right up front the rest of the cash payments including four point. Two billion dollars promised by the sackler themselves. All that money would be spread out in installments. Paid over most of the next decade that really angers critics like more healey. She's attorney general in massachusetts. What the are offering essentially as a way for the payments to be structured. That makes it convenient for them. They get to keep their billions and bank accounts and make money and use the to pay. You know the states out over time while they're oxycontin or chin keeps growly and there's another row bay for critics and it's affected a lot of the ten billion dollars in value. Promise by purdue pharma in this deal doesn't actually come in the form of cash that communities desperately need to pay for things like addiction programs in public health instead. This plan would provide low cost addiction treatment drugs like buprenorphine and lock zone which the new spin off company would make and sell at a discount. Then what happens to the sackler here. Because if the federal bankruptcy court approves this plan i mean they feel any personal thing at all. This is a really big question. After launching oxycontin and claiming it was safer than opioids other opioids the sackler and their company hauled in more than thirty dollars in revenue. Purdue pharma has since pleaded guilty twice to federal criminal charges for their marketing of opioids researchers say oxycontin contributed to this explosion of opioid addiction and death. Now the actors have agreed to give up control of their company. But some critics point out that purdue pharma was already sinking under the crush of all these lawsuits. So it's not clear how big a financial sacrifice that really is. Members of the family also added about a billion dollars to the earlier settlement offer. They made but in this deal they will keep most of their personal fortunes and they'll admit no

Purdue Pharma Brian Man Brian Sackler Family Oxycontin Steve Miller Pharma NPR Healey Massachusetts
Purdue Pharma proposes $10 billion plan to come out of bankruptcy

Our American Stories

00:17 sec | 3 months ago

Purdue Pharma proposes $10 billion plan to come out of bankruptcy

"Billion plan submitted to a bankruptcy judge Monday night Produce Farm, a maker of Oxy cotton would be transformed into a new entity that would funnel profits into combat in the nation's opioid debacle. The Sackler family, Purdue Pharma's owners would pay four billion out of their own pockets. His

Produce Farm Oxy Cotton Purdue Pharma
"pharma r" Discussed on Backstage @ Upstage

Backstage @ Upstage

08:03 min | 4 months ago

"pharma r" Discussed on Backstage @ Upstage

"Having the kinds of issues that christie talking about his in addition to the pharmaceutical companies themselves. And that's a great place to start You know it's a drug that you're locked has been prescribed as too expensive. You can't worded go into the drug company directly and chances are they will have some resources some program that can help without because it's very much in the interests of the company that people aren't turned away or get off the drugs because they can't afford it but putting that aside there's also there are patient advocacy resources that specialize in helping solve these access. Costs challenges one terrific. One that cheryl. And i both know well from a previous work. The called the patient advocate foundation. It's as out of a washington. Dc area and they exist primarily to help patients navigate these issues and they do that every day. There's no patient there's no caregiver or does it every day or has that experienced that group like that brings table so i would encourage people to reach out. Patient advocate foundation and other groups. Like the i help with a lot of people. call navigation. Think that's a good term. That's great to know and so if you were prescribed something for particular from suitable company this is just a basic question who would a patient or care giver contact. How do you know in general. You can't call the main number and maybe you can. What how would you suggest somebody gets to the department or the person who could answer those questions whether they can get some help financial help will. It is somewhat different from company to company. I would say absolutely is to make sure you exhaust all avenues with your own insurance provider because at the you know the drug companies will will make sure that you've done that that's the way our system works so when when those avenues have been exhausted and figure out who. The manufacturer is of medicine in question. Their websites will either be hopefully make it obvious where you go for a patient assistance term of art of has not. You'll search on patient system on a website and and and the specific contact options should come up. It's usually a mixture combination a web address and email address toll free number find those resources on the company's website and then reach out to them. All of the major drug companies have dedicated teams. That answer those calls and the answer. That was email so you will get an answer. That's they can burn very sears. I could maybe interject hair so something has changed over the past five years i would say some companies will say they've had it longer but there have been resources put into hospitals as part of the doctor's office and then they have corresponding resources with the pharmaceutical representatives at the hospital to manage each person's case. So the doctor prescribes it and then he is going to refer you to his case manager. Who is going to work with the patient to get that drug reimbursed help with co pay and make sure that they have access to what they need and win. The patient is working with this case manager and they described that. There's that still too much for them to pay those case. Managers in the hospital now are really trained to know about these resources so i can think of several resources. Cancer care is an organization that has financial navigators you call them and you'll get a social worker financial navigator that will help you through this patient. Advocacy foundation will work directly with your insurance company. And not to mention. If you do look on the website of any pharma. They do have a ton of what they call patient assistance programs. It's not always just cost but it's sometimes it is the resource to help you navigate and not just the cost of a drag but the total impact. It might have on your cancer so they might help you find social workers to deal with your emotional needs or they might help to put you in a direction An advocacy groups that can get transportation for you heard something else like a third not the pharma company itself. But somebody else to help you. So i think starting at the beginning ms your case manager and then kind of going up. The path is the way to go now. I can't agree with you more Because that's that's exactly what we experienced when tony was prescribed. Twenty five thousand dollar drug it was. Here's the scripts and here's cancer care and cancer care will pay for bid deductible that your insurance won't pay for the hospital that we were at did hit a while back in i that's the only experience i know is is going down to the doctor now what to do when your insurance doesn't pay for something. That's the part that part i think. That's that's the gap right like between pharma. One insurance will pay for and then we'll pick up the difference if any so in the end as you look back or you think about your experience with pharma. What's your perspective at this point. I love pharma. I just i just had a great experience with it But i will say this. Though i have a different perspective when i sit back and i see the commercials to me like pharma means it means that people are trying out there working to cure a disease or help someone quality of lights or anything for that matter to me. It's it's now there's something new. There's something better. I just saw commercial the other day for On her hiv. How you can now. There's something out there where you won't transmit the disease anymore so it's just like wow to see that in my lifetime unbelievable it just gives. It gives me a lot of hope when i would hear that there is a new drug affair. There's new drugs in the pipeline. A guide you know. Maybe this will work. And i think that's a great way to to end this discussion today. Which is we shouldn't lose sight of how important it is to develop and produce new medications to help treat people and led people live and you know be a part of their families and have a future. That's the name of the game. We've got a complicated issue here. You guys have provided such great insights into various aspects from the patient to Experts on on the relationships to Communications at hand I the beginning conversation. I hope we'll talk some more at some other time. But i'm so grateful all of you join us for this podcast today to be a part of it thinks eldeen in q. To find out how you can join stage lung cancer in raising awareness and funding to beat lung cancer. Visit our website of stage lung cancer. Dot org we invite you to subscribe and download our podcast available on all platforms. And we'd love reviews and ratings after all showbiz people there's more entertainment and inspiration to come on the next podcast episode of that stage at upstage..

"pharma r" Discussed on The Long Run

The Long Run

07:55 min | 8 months ago

"pharma r" Discussed on The Long Run

"Like it's one holistic framework and I believe that. All investors, all executive should be able to explain this to their employees to you know students when they give a talk at some school like this should be taught in schools. This is just on the mental to the economics of healthcare and the CEO biogen Michelle. He wrote a favorable review for my book on Amazon Right like the book lays all the stuff out. Why would that be I mean by June is currently collecting high revenues for old drugs like Avonex anti, Sabri get non in the years. Why is that? Why would you support a platform idea that in theory threatens some of these drugs we'll because Biden wants to be known for innovation. Let's see how things go with Cam, but that could come to redefine by an biogen can collect high revenues for its new drugs. Then it's not much of a threat than to you know ensure contractual genetic mutation that it's older biologics. A drop in price, right so I think that what we may find out is that while bio versus Pharma seems to create some sort of a schism in our industry even though technically insolence our biotech drugs in that makes Lilia biotech company Hugh Myers abides trucks makes ABC so I can't think of anybody who's not a biotech but. Instead of thinking along the that framework you think in terms of builders versus landlords, and then you come to realize that there really aren't any Pharma's. That aren't both builder like if their landlords at all, if they're currently engaging rent extraction at all on old drugs they're. Also, builders, and so my hope is to appeal to the builder part of the soul of every single company and to inspire the boards and executives that these companies that they. Should be on board with affirming the biotech social contract. Support Congress in passing the right kind of legislation in the right way to make your old drugs go genetic by the way, not even something that these companies can pledge to do if for example, bygone today tried to say. Dear America. If the FDA decides it Adam amount should be approved. We hope that you will make it available to all patients, pay the price that we will charge for me promise that in thirteen and a half years or whatever you end up set saying is like the. Essential brand period that if Warner sizable. That's how long it would be friend. We promise after thirteen and a half years we will drop the price of that drug to slightly north of the cost of production. As if it went generic right, you couldn't hold by to that promise. There's no way that they can call that pledge that I'm aware of because even if the board and executive sweat in the future activists, investors could ultimately take over the company change up the board, changed the rules and keep that drug expensive. Arguably, it would be their their duty to do so because these companies exists to maximize shareholder value. So if today Biden wants to ensure that it's in innovations. Abide by the biotech social contract. Should actually support the no patient of behind platform. In Congress, it has to be a change in the law there there has to be a change in the fight so that in the future by whoever it's led by whatever the board may be is also going to be. Held to that end of the contract it. By the actual rule of law. Okay. Now, Peter? We say you're not allowed obvious. You're also not a political pundit, but it sounds like. You feel like you're getting somewhere like people are listening to you in that builder part of the biotech community. Do you think there's some kind of like political moment here in which like people within this industry are are capable of hearing what you're saying and actually maybe get in the industry to a more stable long-term place so I read a really great book Called Generic. And it was written by A. Healthcare historian Normally has named -gree. was. Barry. Green no If you can find it Chris. You'll save me up I'm so embarrassed that I've It's the my mind. But it tells a story of how the drug industry fought against hatch waxman decades and the fight this one senator coffer and others around. Had to undertake for decades to prevail and bring about what we consider normal that pharmacists can just switch out your your drug cheaper You know FDA approved a generic and it's fine right and that innovation is preserved but they fought and you should see the tactics that they employed. Misinformation to claims that it would kill draw. It would all go. Sideways. But it didn't and so what you're hearing now when you actually see the industry's reactions now you realize this isn't the first time we've been through this. If we just develop an intellectually sound framework and we keep advocating for we will prevail. The trouble is that we're under the gun because we have avoided. Proposing a sound framework for so long arguably, we should have seen not all drugs or go generic even under the BP CI biosimilars Don't apply drugs. We should've known even before then but there were people should have known soon after BBC I passed that. You know it wasn't an award without interchangeability and they should have been able to anticipate that this was coming. I can certainly tell you on art capitals website for over a decade we removed their years ago we said at one of the themes we like to invest in a small molecules of do the job of biologics because small molecules go generic and that's better for society. No technically doesn't maximize your returns, but it still allows for a sustainable. Innovative sector as opposed to one that just maximize your returns in the near term and people would ask about that and I have to explain it. But this was well before. Before I wrote anything it just seem intuitive to me that that's so awesome about our drugs. And so. We should have known better who should've proposed US earlier. Now we're under the gun and whether Congress knows it or not they forced those of us that previously were content to. Just, do our jobs trusted by own Pharma would keep like bad policy at bay they forced us to take notice and say This feels awfully hot here you know I thought bio and Pharma normally shield us from this kind of heat what's going on? It's like Oh. Yeah. This time might be different that are really angry right and so we. Don't have a lot of time to swap out sound reforms. A sound proposal we've no patient up behind a proposal is an example of sound framework, subotic social contract for the blunt price controls that America is now contemplating. So I've been talking to members, of Congress, a lot of them do the the Democrats in particular are open to this line of reasoning. I've mostly been talking to the Democrats right because the Republicans generally have been you know reliable I wouldn't say that they always be reliable but they've been reliable. Reliable. Bulwark against anything that sounds overly lefty. But the reality is frankly to save our country to save democracy we need the Democrats to win right on the we we need.

Congress Biden executive America FDA CEO biogen Michelle Lilia biotech Amazon Avonex Sabri Warner Hugh Myers Cam Adam US BBC A. Healthcare Peter Barry
"pharma r" Discussed on What A Day

What A Day

04:10 min | 8 months ago

"pharma r" Discussed on What A Day

"Of children from their parents, majority of whom were deported back to Central America while their children remained in custody. Even though the ACLU successfully sued to end the practice and ended up reuniting many of those families over five hundred families who are subject to an earlier pilot policy remained separated. The locations of the parents were not reported in three years later, they're still unknown. Local elections and especially sheriff's elections had a huge impact on isis across the country. We put a link in our show notes to some of the most important ones to vote on this year. Just a few days away from the upcoming football season of cities that are home to ten universities called on conference organizers to be more. Cova cautious eleven mayors signed a letter on Tuesday asking organizers to work with public health officials to set standards for things like community positively rates to decide whether or not. It's safe to play a game. Even fans aren't allowed inside the stadiums. Health officials are worried about things happening outside the Games like tailgating in Football Baseball Trie. The mayors also want game scheduled to be released as early as possible, and for there to be fewer evening and nighttime games because as we know in October nighttime is when Pumpkins and goblins come out. I don't see the Puck is come out at night. Conference organizers have not publicly responded to the mayor's request as of now, the first game of the season is tomorrow in Madison Wisconsin. Aches. The Director of National Intelligence John Ratcliffe announced at a press conference last night that Iran and Russia have obtained voter information that they could use undermine confidence in our election system. This came after voters in Florida Alaska and Arizona got that appeared to come from the proud boys if our right hate group which threatened to quotes come after them if they didn't vote for trump, the Department of homeland security now says, these emails actually came from. Hackers in Iran, who take advantage of an unsecured proud voice domain address the hackers also access voter registration information, and the FBI says, Russia access those same files separately the FBI, the press conference Lee yesterday afternoon by saying it dealt with a quote major election security issue. Please for the love of God. FBI. Dispense with hype fragile heart simply can't take these late October announcements. Yeah. We're just trying to. All right. Well, another quick bites the dust. The widely mocked streaming APP Qube announced yesterday that shutting down after raising one point seven, five, billion dollars in releasing a slate of sub. Ten minute shows that celebrities thought of as they were driving to the pitch meeting really fast Kobe was made to entertain viewers who are on the go, but it came out six months ago when we were mostly on the stay that led to week subscription numbers and at the time quickly founder and advocate Jeffrey Katzenberg. said quote I attribute everything that's gone wrong corona virus everything Mr Katzenberg if you're trying to make me stand up for cove it, I, won't do it frankly you should be ashamed of yourself following the great qube shutdown it will attempt to sell it shows and will return it's remaining three hundred, fifty million dollars to investors. If you get money back from Qube, please give it to a loved one to bury a secret hiding spot because honestly lost your investing privileges. Honestly the return on the investment will be as high in that secret. I mean if that money on fire more people would see it and those. That's all for Xanthi like the shirt make sure you subscribe the review invest in Wadi are short-form streaming APP on the way until your friends listen. And if you're into reading and not just major election security updates like me, what day is also a nightly newsletter, check it out and subscribe at crooked dot com slash subscribe ign Akilah Hughes I'm getting interesting and don't Disney puts you around if you're making grey's anatomy and scandal and how to get away with murder, the least you can do is get on the jumbos for free. That's right. You could get away with murder for making all those shows for Disney s May..

FBI Kobe football Iran Disney Russia murder Mr Katzenberg ACLU Central America Xanthi Cova Madison Wisconsin Wadi John Ratcliffe Department of homeland Florida
"pharma r" Discussed on What A Day

What A Day

12:17 min | 8 months ago

"pharma r" Discussed on What A Day

"pharma r" Discussed on Sounds of Science

Sounds of Science

03:25 min | 9 months ago

"pharma r" Discussed on Sounds of Science

"The parent molecule and these soil metabolites can also be taken up into the crops and subjected to plant metabolism. Also, if slow metabolism extensive unregulated company outside is generated, then we will find radio products in plants. So for example, stock gray. So the actual metabolic pathway can be very extensive lots and lots of different metabolites which require. Identification. So the vast majority of work on these studies is not spent on the life as spent in the Laura trae revamping extraction from Mike -cation. So. How do you see this work fitting into? Charles. Rivers, larger goal of supporting sustainability. I believe these chemicals in agriculture offers considerable benefits by contributing to sustainable production food feed across the globe government set high standards for the registration of Anchor Chemicals to ensure. They may aren't health environmental safety standards. The vote that the plant metabolism department does contributes massively to human decrease safety since we define what metabolites full in foodstuffs. Good understanding of how agrochemical behaves of these crops. We cannot make judgments on if it is suitable for use and how to monitor those foodstuffs derived from. It went ask follow questions about specifically how to care for some of the more exotic plants. So like for example, we can go with the bananas. I understand bananas are tropical product. So how how many different variables do you have to take into consideration when you're trying to grow them in Scotland okay about his opposite from tropical as you can get get the biggest challenge to Groin Bananas in Scotland as. Well recycle. That's still them. As as we we see the first one is getting. So. We got up and honors from the Canary Islands which off the west coast of Africa. We purchase those boatmen to the south of Spain and then roll them into the. Probably three to four months to setup. We also need high specification glasshouses which we have on-site here. With heating lighting. Tring on people who have an understanding of the whole Toco check. Does a horticulturist need to be specialized in something like that or is that part of the General Curriculum? Someone who's training hold culture is not easy to find. That not not nota gun that someone who can grow a plans. And Maintain A. Through its life cycle and the plight of plants that we grow hair a not necessarily. Scottish. So we need people who will be able to grow anything from Pinellas to wait to. Will thank you so much for taking the time to talk with me Simon. It's been really interesting to visit the site here Denver. On, thank you. Thank you..

Scotland Anchor Chemicals Mike -cation Charles Canary Islands Pinellas Spain Simon Denver Africa
"pharma r" Discussed on Monocle 24: The Bulletin with UBS

Monocle 24: The Bulletin with UBS

03:10 min | 1 year ago

"pharma r" Discussed on Monocle 24: The Bulletin with UBS

"Typically have seen takes a really long time to develop and the reason for that. Is that you you need to make short safe and you need to put these things you start with a very small number of patients and then you find the right the right dose or doses that you think might be a good idea then you take it into a larger number of patients and ultimately put it into a very large number of patients in the thousands for a vaccine maybe even thirty forty fifty thousand people and the reason you do that is that you are looking for safety. Maybe very rare adverse events to safety episodes that you wouldn't see in this you put it into a lot of people over a long period. The other thing to bear in mind or the vaccine is with a drug typically we we find people we give from the drug and we wait to see if I get better with a vaccine. You do the opposite. You take healthy. People give them your vaccine. And then hopefully don't get sick. And typically second processes is much more protracted than the first process. What we are going to right now is witnessing potentially very accelerated development of vaccine and there are certain vaccines already that we can produce very quickly so for example on show. You know that each year we there was a different flu vaccine. In fact there are actually three or even four components in vaccines to different viruses. But we're able to devote one of those quite quickly because we have a process we're doing every year we effectively just change out which strains of flu we're trying to vaccinate against this is a completely new virus. So it's not quite. It's not as quick as we're looking at new and different methods of vaccine production that maybe beans apart the rnd landscape in the background but are now very much funds incentive with the question is could we use them to help get a vaccine against so attuned very quickly. So I think a lot of a lot of what you see in the news is is very interesting. We see companies like Madonna for example in human trials already and possibly progressing to face to face three trials very rapidly. So it's GonNa be an interesting process because it doesn't give the the sort of time that you would usually need to see what the level of effectiveness really is. We'll probably be moving forward just based on what we can see of safety in the short term and then kind of playing playing catch up as we go through the process but potentially we could give oxygene books. Law Kids cried quickly. Either from Madonna one of the other companies or alliances trying to develop something in the space and hopefully in the future will be better prepared for a conduct like this and hopefully we learned to. I'm not slower sutcliffe bringing us to the end of this issue of the bulletin with UBS. Setting the agenda in the fast-moving blow to finance each week here. On Monaco. Twenty Four. Listen again and find out more. Monocle DOT COM. We'll catch up for your preferred podcast. We'll be delving into the future of healthcare and considering how technology will continue to drive innovation in the space on next week's program when we meet another of vs extraordinary global visionaries and harnessing tag to revolutionize the delivery of medicine and surgery. Sure to tune in for that you be s twenty four..

flu vaccine flu Madonna Monaco UBS sutcliffe
"pharma r" Discussed on Monocle 24: The Bulletin with UBS

Monocle 24: The Bulletin with UBS

14:21 min | 1 year ago

"pharma r" Discussed on Monocle 24: The Bulletin with UBS

"Week the sharpest minds the freshest thing in the world of finance take you beyond the numbers hype right to the heart of the big issues of the day in recent weeks the investment landscape like that in the media just about the less frankly has been dominated by the Global Corona virus outbreak and today Alpine is going to discuss the potentially enduring impact of the pandemic on how healthcare is delivered. We'll ask whether broader trends around the digitization of the space will continue to be accelerated as we've seen thus far we'll also consider some of those areas less impacted by the disease and its aftermath. And we'll look to what else in the sector is. Seeing interest from investors away from the more immediate and intuitive areas like diagnostics and telemedicine also in focus on the program we'll be pharmaceuticals from gauging. The challenges of Vaccine Development to the risks implicit in developing new products and technologies in the sector. We start today with Lackland towered equity sector strategies for UBS wealth management as. I just mentioned that a pandemic seems to all my stomach. Everything the new cycle the whole discourse really. Can you give us a sense if you can have exactly how profound the impact of this outbreak is going to be on healthcare as a sector on how that healthcare is and will be delivered going forward there will be a large number of changes just as we think that will be a large number of changes in the economy and broader social changes that followed in the public in the near term most of the healthcare companies Holding up reasonably well but there will be some disruption if we try to be on that disruption one of the things that we have seen. That is a real step change. And we've seen this in the last. Few weeks is demand for remote treatment or for telemedicine. We've seen a huge says of interest in this because hospitals are busy looking off to patients in the DEMOC and of course other patients don't want to go to the hospitals as well at the moment Give you data points leading telemedicine company in the. Us recently said that they'd seen a fifty percent increase. In visits this was doing much appetites have surged and the US. Government has even spawned this and has loaded the regulatory barriers. That were part of the reason. Telemedicine had been held back in the past. So it's early signs and this is only one area. But I think we're seeing indications of this has been adopted quite quite rapidly so looking does it therefore follow that that interest in telemit's specifically but I guess in the whole sort of digitalization of healthcare generally will outlast the pandemic. I mean I guess that's that is the strategic sort of question to ask at this time. I think it's a great question. We do believe that both telemedicine specifically and the polka trend of digitization hell cat will end on time investable trend sesame on telemedicine specifically we think one of the reasons telemedicine hadn't used what it was. Tyson's just went away and of course patients have reluctant to try something new as well. Both of those issues that I've been changed have been addressed by the pandemic so if some of the people who have tried it turns out they like it. And we expect telemedicine lost on the broader topic of digitization telemedicine is only one part of what we call health tech and this is really a trend about increasing use of digital data communications remote monitoring to deliver health cap and we know that the world spends an enormous amount of money on healthcare. Loaded up money is wasted and a lot of that could be spent more efficiently so with the demographic trends that are driving that increased healthcare dimond having a way to bend the curve down and get more value for money in the money that we're spending is absolutely necessary. An incredibly valuable so healthcare is a system or health. Care is a system has not used enough. It's in the past. But then no mismatch of data in the industry something like five percents data in the world is generated healthcare system and if we can use that data and if we can use new technology five G. to better communicate and get data into the hands of physician sooner than we think outcomes can be. We think it isn't investable trend. We think this is the white coat that people will realize. It's it's important that we expect us to continue over the long term. Well if we top then look into more broader question around invest ability across all of healthcare. What about those areas that are not so directly impacted or affected by the pandemic plainly? You've described telemedicine this. The digital realm is absolutely fundamental. It's right at the heart of the discussion. What about areas that are that are less immediately impacted? That's also a very important question as you said earlier the pandemic dominating and you cycle at the moment but if we step back if we step back and look at healthcare more broadly if we look at the illnesses and the health challenges that people have to deal with over time we see a different picture so take cancer for example cancer the second leading cause of death in the world and nearly ten million people died of cancer in two thousand eighteen. We know that cancer is linked aging. And we know that well population's aging so that number is going to go up. We spent the number of new cases of concept to keep rising for at least fifteen years at double the right to population growth and we've seen progress but survival rates are still hovering around sixty seven percents in the US and they've been there for at least the last five years so there is more to do as more to do from a social perspective. There's more to do from an economic perspective because the cost of the global economy of cancer zyppah trillion dollars a year and we think there's more from affirmative perspective because around one third of drugs in the global drugs pipeline. I've actually talked in cancer. So there's a huge opportunity here and to answer your question. This is absolutely unaffected by the undamaged. It was a problem last year. It's a problem now and it will still be a problem next year. So we think this is very interesting. Investable what are the risks? Implicit in not just oncology lack lamp but in all of the biotech space the biotech. The primary risk is the failure of the drugs company pipeline and it's inevitable that some of the drugs will fail so we think the best thing to do is to accept that risk but try to mitigate it my building portfolio so you can diversify across different therapeutic areas you diversify in areas such as oncology but you want to build a portfolio of companies that allows you to control your exposure to the risk of failure of any one individual put any one individual company. Tower is important to keep a focus on the longer term secular trends. Is it Jemaine to say that those themes that we've discussed before on this program will be impacted in the short term? Yes but there are also things. We need to keep front and center in order to make better decisions in pursuit of exactly the kind of well balanced portfolio that you were just mentioning there. I think it is Jimmy. I think it's always relevant to look at the long term trends and in fact our clients are looking all the time for those long term second investment trends especially at a time when you have seen a drawdown in the markets if this could make some of those more attractive entry opportunities for those trends that we think are essentially unaffected at a fundamental level by the kind of pandemic. So one of those for example would be genetic therapy's which I believe we talked about before these Treatments that are intended to modify patience. Genetic information so that the information inside that sells to get at the underlying causes of disease so the tensely one time cure for certain inherited diseases. Something that is potentially a pass on shift in medicine if it can be broadened out to treat a wide range of a wider range of treatments. Luckily if we can finish house by coming back to to where we started and considering how this pandemic has altered the landscape. Do you think that the current health crisis because of its scale because of its geographies? It's almost everywhere is a game changer. For the healthcare sector. Or do you think we need to be a little bit cautious about that and actually four large areas as you've already described it's kind of business as usual and it probably will be once. The worst of this is over. Is there a risk of looking at this as as an inflection point I think one of the things that will change for the drugs industry as a result of the dynamic? Is that an industry that had been under a lot of political pressure. You remember. There's been lots of media attention price of drugs in the US. For example people have realized now that found the companies can also do some good and so can other parts of the healthcare system is don't be the hospitals and the workers. This is very clear but also parts of the industry that didn't get a lot of focus before like diagnostics industry so it will be very important with the newly developed tests to understand how. The pandemic is progressing. These questions will still undecided. We're still waiting for important data but I think the political environment media environment around the industry and that is important for investors because it has been weighing on stocks. I think that now as she could be changed somewhat by the realization that companies appears to be delivering towards helping to his apartment. Let's hear next from Laura Sutcliffe. Phd UBS Investment Bank lures area of specialism is pharmaceuticals research. Laura what are some of the sector-wide dynamics across healthcare across all farmer in fact in the context of this new scrutiny investor interest and media interest across the space in recent weeks? You're absolutely right. A lot of interest in health care not just following a broader healthcare as well and unwise. Wouldn't there be because ultimately. I think solution to the predicament. That we find ourselves in the moment is probably only going to come by developing drugs in developing a vaccine for foreign companies. I think in some ways they have very different dynamics and other businesses so in general are D- continues. People are looking at these businesses to do something rather than to shut out at the moment. And I'm sure you've seen in the news press releases things like that about some of the some companies laws. I'm small really guessing. Involved IN ESSENCE. You either drugs repurpose old jug or contribute to the development of a new vaccine so these sort of high profile projects are. I suppose of some of the social responsibility that these companies have these unlike to be put up that make much profit if they get from the. Okay well certainly are no reasons to invest but these these kind of are indeed projects are underway at the moment Interesting I think to a whole cross. Section of people and unwind off despite that unique backdrop. All of what's going on at the moment I wonder. Is it ever more important to try and ignore if you like the media white noise and keep focused on the big picture on the longer term trends? It's important presumably to strike the right balance here. Well I think that's right and for a lot of businesses sort of follow business especially big ones. What's going on sort of Doesn't doesn't stop so in the financial markets people are looking maybe to twenty twenty one already. They've already accepted that this will be a year of disruption so I can understand on a personal note why people are very keen to know if there will be a good truck for treatment when of oxygen might be widely available. That sort of thing but yes Like you say there's also a much longer term view on the future of these businesses which I think is probably quite safe in the in the context the former but also from the perspective once West. Through the the short term lumps and bumps that this cording what the role of these businesses as might be an longtime preparedness lure browsing some recent research notes and reports. You've been producing in recent weeks as part of UBS's ongoing work here. There are some interesting notes on risk in this sector and obviously if we look at Pharma and particularly I guess this was in the context. A piece you wrote and explain her about the development of vaccines but just the way. It might be interesting to get a sense from you. About what those risks are particularly this this question of of development risks with with new drugs with clinical trials and so on. Because that is again. It's very front and center at the moment. Just tell us a bit about about the risk profile here and don't wait. The risks are not changed by the short term existence of upon them. It right so developing drug is a very long process. One that people keep trying to make shorter. And the I think the risks in that sector folly well discussed you out of every ten or twelve dogs that makes it into Ali trials. Maybe one guess Tamaki terribly expensive and like I say it takes a long time in fact scenes of maybe a little bit different. It takes longer to find a really good one but they tend to sort slightly better success rate between the different phases of development. And then actually they. They have quite good characteristics in terms of how much risk they present in futures. They sort of have they patent expired in the same way that that drugs do so. Those things are quite different. Risk profiles for the risk profile doesn't change. I think too much at the moment. I think. Maybe you see people delaying trials and little bit because people are home or that come about recruiting patients but the level of risk I think to drug development is the same as it was before paps. Finally can I ask you about the the quest for vaccine? There's a scrutiny illness. Of course like never before for obvious reasons but what should people bear in mind? I think ties to some of the things we were discussing earlier..

US Vaccine Development Laura Sutcliffe Lackland news press Phd UBS Investment Bank telemit Tyson Tamaki UBS Jimmy D
"pharma r" Discussed on America Dissected with Abdul El-Sayed

America Dissected with Abdul El-Sayed

06:16 min | 1 year ago

"pharma r" Discussed on America Dissected with Abdul El-Sayed

"So there's a there's sort of an insulin in access problem where you know ineffective because of all this They're going to be people who can't get the vaccine simply because it's owned by one company that could be a very real possibility and you know the companies will say. We're not going to do this. You know it's a pandemic we understand but that logic is very insulting you know because you've been saying you're committed to access and affordability but what have you been doing for the past decade. You know. We have people in this country who are dying because they can't act as insulin. You know we. We have an HIV epidemic. That is not being curbed because TRAVIATA. Prep was at ahead a list price of twenty four hundred dollars a month. You know what what makes you think that these companies who have been price-gouging us for decades are suddenly going to turn around and in this situation be like. Oh yeah you know we're working on Providence non-profit basis and we'll we'll make sure did to to supply everyone at an affordable price if what we have seen from the companies in the past is any indicator of how access and price and supply is going to turn out. We're going to have massive problems not just in this country but globally as well. We could have a unprecedented moral catastrophe. Where a few countries supply a few countries are able to get the supply and the rest of the world is completely shut out. And you see the virus just spreading unchecked. I want to think about now. What are the solutions like? How do we fix this? Why are we so vulnerable? And what should we be doing about it? The good news is that these are all choices where making and so we can make different choices. There's really three things that we need to prioritize. One is that there should be no monopolies on any Kobe. Nineteen treatment or vaccine you know. Some companies are actually stepping up. Some drug companies have relinquished their monopoly rights and have allowed generic competition to to in supply in some in some cases and if the companies don't do that then the government should step in the government has the inherent authority to use patents to break monopolies and to allow generic competition and to allow suppliers. The government should do that one two. We need to massively skill up production so that means pouring much more money into scaling up both the public private production facilities and also getting the pharmaceutical companies in line to get ready for these treatments and Vaccines. Ideally want to treatment or vaccine is proven effective issue. Be available to everyone world as soon as possible but right now we have. We're going to have time gaps. We're GONNA have time legs and we don't want any of that and so we need to be getting ready to for a situation in which we have the treatments and vaccines stockpiled waiting. Ready to go ready to be deployed as soon as we fit configure out if they are safe and effective and a third thing. We need is global cooperation. You Know President. Trump has made some pretty horrible remarks about the World Health Organization and the World Health Organization is certainly not without its flaws but a key element of this crisis is that it is a global crisis. Nobody really knows where the tree back seen will come from you. Know countries around the world are spending millions of dollars for research and development. What we need is a global system that allows companies and countries to share knowledge to share manufacturing. Know How to to work together to be able to address this common challenge. I really really appreciate you taking the time To break that down for us and help us to understand How the system works and what. The potential dangers and traps look like. How are you spending this moment? what is what is what is your Quarantine life look like. I work on these issues day in day out and it still hasn't really hit me yet. I'm looking at what is going on and what the world could be and it just it's it's terrifying but the full scale of the crisis really still has not hit me and I think part of it is. I've been doing a lot of reflecting this crisis. The key question asks of US is who we consider disposable. We're making choices right now. That could shave. The lives of billions of people and none of these choices are inevitable. None of these paths or the natural way we decide you know in the past. We've chosen disastrously the global AIDS epidemic. That is still going on and we let millions of people die because of the high price of medicines. I've been really just trying to think about. Are we capable of making that same mistake again? Is that the path that we WANNA go. Are we going to face another moral catastrophe? And I just I I. I hope we don't I hope we don't well. I really really appreciate Your leadership in this moment in making sure that we don't and Thank you for joining us today and And for laying out Rizvi. Thank you so much. Thanks so much as usual on our way out. I want to tell you what I'm watching right now. Cove in nineteen is having a major impact on the American Food Supply. Restaurants and caterers are a major source of food consumption and without them. Food demands falling through the floor. Meanwhile cove in nineteen is making factory operations and shipping nearly impossible. The result dairy farmers are leading milk flow down the drain and major.

World Health Organization US Vaccines President Trump Rizvi
"pharma r" Discussed on The Highwire with Del Bigtree

The Highwire with Del Bigtree

09:57 min | 1 year ago

"pharma r" Discussed on The Highwire with Del Bigtree

"Right. We have a lot of new viewers. That are maybe not aware of the plot and deposition but just so you know One of the issues. We've always had on this topic. Is that we get attacked by like I said these people that have no reference point. They don't they're not immunology specialists we also have scientists and doctors and we said. Look. Let's have a debate. Let's just sit down pull off? It knows better. Stanley parking knows better. We have some scientists and doctors and lawyers. That would love to have this debate with you about your science to some of the things we just prove. Cdc where Your Studies in the end? They didn't have the studies. They said they've had they have but we got lucky. We got lucky I think is now a couple of years probably two years ago now. I'm sort of losing track of time because so much is going on but Dr Stanley. Plotkin is degraded the godfather of the vaccine program and there was a divorce case. Going up in Detroit Michigan where the father wanted to force vaccinate the child even though there'd been agreement with their wife when they were married to not back sonate the child now he wanted to force backs and he's actually something we're seeing. Horrifically happened across the country. Usually it's the father but sometimes its reverse but it's a way to try and get more you know to really inflict pain upon the spouse is to do something they know that they don't want which is vaccine the child and they also use it to get favor with the judge and try and get more visitation rights. It's really ugly and it's happening all over the place But this was one of those cases Dr Stanley Plotkin the leading authority on vaccines decided that he would go in to be a witness for this child and why the child should be vaccinated. This is a nine hour. Deposition you can find online. I believe the transcript is out there. Also we have shown many parts of this than segments. This is a section where we actually you know where it's discussed with Stanley. Blocking the idea of a vac vs on back study why not just do want so much could be answered there. And while you're gonNA hear is a lot of the same type of argument that I heard when I was at a meeting at the National Institute of Health Bobby Kennedy and I and several lawyers and doctors and scientists were all invited by Donald Trump to meet with luminaries of our vaccine World and we asked him. Why don't you just do a Baxter's on back study? And they said to us we never will we hear inklings of. We don't know how to control different arguments. Well this argument is put tash now. This is a fairly long segments. Y voided for a long time. And we're about to really geek out so if you're not interested in science or you don't have enough brain cells left right now. I totally understand. You're not into it and you can tune out now but for those of you want to watch. This is the type of thing I really get into this. Is what the producers here at at at the high wire really dive into in care about this. Discussion is fascinating. But it's going to take a little bit of an education so very quickly. I want to give you a couple of terms you need to understand. You're listening to it so that you can understand what's going on so first of all. Let's look at this term a Founder confound was a founder is something other than the thing being studied that could be causing the role. Zolt seen in a study now. This is a real issue when they do demographic studies when they look at a large population. They compare one group to the other. Is there something? We're not seeing a hidden thing that could be causing an outcome that misleads us one of the examples you'll hear about a founder is imagined someone decided to do a study about lung cancer. And what they did was. They looked at people who drink twenty five shots of vodka. Let's say a week and they show that people who drink twenty-five shots vodka a week end up having higher rates of lung cancer then those that only drink two glasses of wine now study could then prove that vodka causes lung cancer except founder that you would be overlooking people that drink twenty shots or thirty shots vodka tend to also be more likely to smoke cigarettes and that would only you would only know if you really looked at more details in the person so if you don't you know isolate the cigarette smoking then you're going to get a false positive so then you would take out all the people that drink twenty shots subotica and also smoke cigarettes a pack a day or whatever it is and you would find that those levels might even at least the example that I've been given many times. I hope that helps you understand it. So the compounder is something that's GonNa come up. Give me another hour. There's another term. I want you to understand because we hear it. A Lot. Pert retrospective study. A retrospective study looks backwards and examines exposures to suspected risk or protection factors in relation. An outcome that is established at the start of the study. So in retrospect study just like it sounds is in reverse. It looks back so this is people that have already eaten whatever food you studied or already taking whatever drugs they take or already covered whatever pesticides or breathing. Whatever you know. Fumes are coming from the factory down the road because you know in this way we can go back and look at those that you know took this drug and those that did not and not affect those people at all because the other term we always here is. We will not do a placebo study. We will not do a placebo study because they will put people at risk. We can't have people not getting lifesaving vaccine when they're talking about that. This is the term. They're using a prospective study a prospective study watches for outcome such the development of a disease during the study period in relates to other factors such as suspected risk or protection factors. Now remember virtually every drug we take goes to a prospective study. Vaccines do not. I think you now have enough definitions to sit back and remember that. This is not an informed consent action network case. This was a personal case in a divorce up in new in Michigan. But what you're going to hear is the lawyer for the informed Consent Action Network ahrends theory. I almost accidentally just said Doctor Erin. Siri he would laugh at that. But when you walk this you'll get a sense of. Why almost made that slip? Watch a lawyer take on one of the greatest scientists in the world and watch how the scientists tries to confuse him but fails very badly grab some popcorn. Enjoy Dr Plc. And has there ever been a study which looked at the total health outcomes of children following the CDC's vaccination schedule and those who are completely unvaccinated? Such faith not that. I'm aware of. Why is it studying up and done probably because It is considered bad malpractice. Not to vaccinate that child. So you're saying a prospect of study is might be improper because we'll leave a child unvaccinated. Correct okay what about a retrospective study? That I suppose could be done but it wouldn't be randomized. You're familiar with the vaccine. Safety data link yes. Are you aware that there are a few thousand children's that are my understanding completely unvaccinated? Vsd Oh I don't doubt it can couldn't edit vaccines safety. Data link us to conduct a retrospective vaccinated versus unvaccinated. Study to look for health outcomes. Well I don't know theoretically perhaps but One would have to Be Convinced that the children were were compare comparable in in other ways besides being vaccinated or unvaccinated. Every time you a retrospective study that you always need to control for potential co-founders correct correct and that's what you're talking about controlling for co-founders right. Yes CD Pharma. They conduct studies all the time. Right yes yes including studies that have co-founders that needs to be control for right. Yes vaccine right yes. You Vaccine Studies especially for efficacy happen all the time correct. Yes clock and I'm GONNA hand you. What's being marked as exhibit plaintiff's Exhibit Twenty three? Sorry do you Dutch plug. And what's it is CD nine code. Well it's it's Essentially way of coding diseases for usually for remuneration purposes. So when a doctor administers drug or diagnosis. A patient or something similar. They are as a code that they would answer into the system right. Yes and the ICE CD. Nine codes are published by the American Medical Association. Correct yes okay. So if you go to the second page do you see? There's a code. The six four point zero seven. Yes what is that code for a vaccination not carry out for religious reasons. Okay so wouldn't it be feasible for example to compare children? Who have this coding who are not being vaccinated with those who are being vaccinated. Who are in similar. Communities have similar demographics and otherwise avoid as much as possible other potential co-founders. Well if you could eliminate the cofounders it would be feasible. Can you tell me co-founder that's not easily easy to control for.

founder Dr Stanley Dr Stanley Plotkin Cdc co-founder Michigan lung cancer Detroit National Institute of Health American Medical Association Donald Trump Bobby Kennedy Baxter Zolt Doctor Erin Dr Plc CD Pharma
"pharma r" Discussed on The Highwire with Del Bigtree

The Highwire with Del Bigtree

13:10 min | 1 year ago

"pharma r" Discussed on The Highwire with Del Bigtree

"It now. You only knew that from doing marge. Clinical Trials with tens of thousands of people. I mean I think that because we falsely overrate or incorrectly rate. Listen to this. We falsely overrate or incorrectly rate. What the mortality rate is. We're willing to accept. The things will be rushed through back. Corona virus doesn't have a high mortality rate. There's a virus that the CDC currently estimated his killed between twenty thousand and forty five thousand people in the United States Influenza. But only half the country gets that backsied. There's only fourteen deaths in the. Us has a Friday afternoon from Kobe. Nineteen but everybody would get a vaccine now. The point being were not very good at assessing risk. I think that's really quite informative and shocking to be coming from Dr Paul Off. I was scratching my head saying. Isn't this exactly what he wants to rush into a vaccine and isn't that what he wanted? One every adult on the planet to believe that we need back scenes. Orders Survive yet. He's being very cautious. If you don't find that shocking enough there's another person that likes to attack us all the time attack me all the time Dr Peter Hotels who actually works at designing vaccines. I'm going to agree with him or in fact I think in this case he really is actually agreeing with me. Because he's about to tell you know in front of I believe. This is the congress that is in front of yes. Oh speaking in front of the Congress. This is what he had to say. And by the way I already told you much of this a couple of weeks ago but here we are me and Peter. Hotels like this saying the same thing. Take a look. We partnered with a group at the New York Blood Center in Galveston National Laboratory to take on the big scientific challenge of Corona virus. Vaccines and I say a scientific challenge because one of the things that we're not hearing a lot about is the unique potential safety problem of corona virus vaccines This was I found in the early nineteen sixties with a respiratory virus vaccines chill and it was done here in Washington with the NIH and children's National Medical Center. That some of those kids who got the vaccine actually did worse. And I believe there were two deaths in the consequence of that study because what happens with certain types of respiratory virus vaccines you get immunized and then when you get actually exposed to the virus you get this kind of paradoxical immune enhancement phenomenon and what how and we don't entirely understand the basis of it but we recognize that it's a real problem for certain respiratory virus vaccines that killed the RSV program for decades now. The Gates Foundation is taking it up again but when we started developing a corona virus vaccines in our colleagues. We noticed in laboratory animals that they started to show some of the same. Immune pathology that resembled what had happened fifty years earlier. We said Oh my God this is going to be problematic. These clinical trials are not gonna go quickly because of that immune enhancing. It's going to take time so all and unfortunately some of my colleagues in the biotech industry are making these inflated claims. You've seen this on the newspapers. We're going to have this vaccine in weeks or in this and that what they're really saying is they can move into clinical trials but this will not go quickly because as we start vaccinating human volunteers especially in areas where we have community transmission. We're going to have to proceed very slowly very cautiously. The FDA is on top of that they have a great team place at the Center for biologics Evaluation Research. They're aware of the problem. But it's not GONNA GO QUICKLY. We're going to have to follow this very slowly cautiously to make certain we're not seeing that immune enhancement so now we're hearing projections year eighteen months. Who knows pretty shocking? Right I mean to watch these guys. They're usually screaming vaccine vaccine vaccine. It's all coming all of a sudden. They're tapping the brakes. But I really WanNa address the fact that we already covered this discussion. In fact we gave you a lot of detail more than two weeks ago. This this speech happened on March fifth but Two episodes ago I actually brought up the animal studies that Dr Houghton says is referring to. I want to show you this because these same people that are agreeing with me. This week tend to say that I'm spreading misinformation. But the truth is that we're bringing you information even before the scientists are. I have proof of it this time. Take a look what I told you on this show. Two weeks ago about the animal studies. Immunization was SARS Corona virus vaccine leads to pulmonary immunopathology on challenge with the SARS virus the long section suggesting hypersensitivity that was reminiscent of the description of the type. Immediate pathologic reaction in young children given an inactivated. Rsp S. V. Vaccine and subsequently infected with naturally occurring RSP. This is an older study. Here was the conclusion from this. Study's this SARS covy vaccines all induced antibody and protection against the infection. They seem to work. However when challenged challenged given any vaccines led to currents of T. H. Two type immune pathology suggesting hypersensitivity to source. Kobe components was induced. Caution look this caution and preceding the application of a Koby vaccine in humans is indicated so this study even went on to say what we're series seeing reminds us of a human study. We did on children. Totally different vaccine are be where they seem to do. Great with the Vaccine. Antibodies but then when they came in contact with the disease they actually had hyperstimulation reaction. What they found was the body took in more of the virus with the bacteria. This this is something that's known to happen on occasion and made them more sick than they would have been and as you know. Hotels went on to say something called immune enhancement for some reason. The vaccine appears to create. Antibodies and the person or the the animal using it in in the children was with RSP but then when they come in contact with the illness that the backs are supposed to protect them from for some reason they have a hyper stimulated calling immune enhancement reaction. And as as as Peter Hotels said we don't really understand it. We don't understand why it happens or how it happens. And that's why we need to proceed very very very cautiously as we move forward. He even sort of you know rags on a couple of his. You Know Fellow. Biotech companies are saying we can this in twelve months to eighteen months. He's like yeah. We'll see now. Part of me really found myself grappling. With why all of a sudden is Peter Hotels tapping the brakes and Paul off at tapping the brakes and it really made me realize that because something is about to happen. That's never happened before. In fact it may be a really strange type of gift you see. What's about to happen is a vaccine trial as stage. One vaccine trial under the microscope of the American people of the world actually billions of people are about to watch this study. Take place here it is. Let's go back to that headline Kaiser Permanente washing enrolling participants in First Corona Back Seen Trot Grun virus vaccine trial. Moderna is that name of Modernist Corona Virus Vaccine Ready for clinical trials as pressure. Crooner BUYS THE VACCINE. Mount scientist debate risks of accelerated testing. They're gonNA crank the Seattle Seattle gets burst. Go AT CORONA VIRUS VACCINE TESTING. And then of course. We know that we're being told forty five individuals. Here it is. The initial trial will need forty five healthy adults. Jackson said that no research participants will be given a placebo. What wait a minute? I thought we just heard Tony. Foul she saying to us the gold standard for approving a former student goal product in the drug trial. You know that they're doing. He said the gold standards of Placebo based trial yet with the vaccine. We're not gonNA use a placebo. You see normally they get away with this and this is what it led me when I was thinking about Paul and Peter Hotel. Has you see the problem they have? We are now all watching this because of the work that we've done with the informed consent action at work because so many of you are sharing the high wire with your friends. You're Al- alert to this. Now you say wait a minute. Why aren't they using placebo? Especially right now. Even if the study that we know that studies only GonNa last about four months. I've already pointed out. I don't know how you're going to establish safety in forty five people with a four month study. There'll be no look at long term side effects autoimmune immune disease future cancers or the fact that once these people if it actually ends up being like the animal trials or like the RSP trials. What happens if you give these people the vaccine they look perfectly good performance and then they walk out and they happened to run into somebody with Corona virus? They get it and they'd I their body supper Munin Hansman. They have an absolute you know meltdown aesthetic kind storm takes place in their body. Which is what this thing can cause and they drop dead then what happens and then I started thinking about the fact that do you realize that usually you know this stage. One type of trial takes place outta sight outta mind is happening inside of a pharmaceutical clinic. They happen all the time. Most of them fail mostly drugs and vaccines. Don't get out of those trials because really bad things down now think with hotels auditor thinking. This isn't going to be good for the program if People Watch what if one of these forty five people dis? What if Ted them get really sick? You know what if they all end up having massive upper respiratory problems? Then what are we GONNA do? How are we going to explain that? I mean we can use our use our usual antics and say well you know. We didn't have a Placebo Group. So it was natural that one of these people would die or you know people get upper respiratory cold going around people get the flu you know yes. They got the flu it happens. They'll try to explain the way but never before has the entire world been waiting with baited breath watching forty five people entering a stage one trial. I think that's what's got Paul off it and Peter Hotels really nervous. The pharmaceutical industry has never ever wanted to try and do something like this under a microscope. They liked being left alone. They like having time to figure out what they're talking points are are we gonNA know who these forty five people are in better yet. I think we really ought to talk about these individuals because in my mind they are making a gigantic sacrifice for us. Four for whatever. This corona virus is no matter how deadly it is or is not what we know is that attempts at this vaccine have been deadly in animal models have been deadly. You know we know that ours be killed children. We know that Dan gave axe killed children. We know that people die. And even though you're only testing this on perfectly healthy people right and so what are we going to even learn from that? I mean forty five healthy. We know that healthy people tend to not have any symptoms or very mild symptoms anyway. Why aren't we testing this on the elderly? This seemed to have really extreme reactions. Why aren't they the ones being tested on? Since they're the ones that need it most see all these questions should be asked but what we know is we're going to go and get forty five extremely healthy individuals and give them the theme that after animal trials there were massive warning saying be very very careful. Moving forward forward with human trials. You even heard to say that. It was so devastating. What happened with RSP that we bailed out of even attempting to create an RSP maxine. Well Bill Gates is working on one. Now let's make everybody happy that he's returning to the cause but they'd given up on it. Corona virus is not an easy vaccine corona virus as they have said with the common cold. There's no cure for the common cold. You have to assume they'd been attending for a very very very long time to make a corona virus vaccine and now suddenly they're going to rush into stage one trials..

Dr Peter Hotels Dr Paul Off RSP Us congress flu Gates Foundation CDC Bill Gates Kaiser Permanente Seattle Washington NIH Dr Houghton Placebo Group Kobe FDA Dan
"pharma r" Discussed on The Journal.

The Journal.

08:49 min | 1 year ago

"pharma r" Discussed on The Journal.

"This episode of the Journal is brought to you by verizon. Horizon Prides itself on being reliable as a phone company and as a business partner that means keeping businesses ready for the future with artificial intelligence security features and new technology like verizon five G. Ultra wideband. It's ready to change the way business. Operates digital transformation. Never stops verizon keeps businesses ready for what's next find out how at verizon dot com slash ready y. Welcome back trump because problems for Pharma even before he took office in Trump's first press conference after he's elected which is in January. Two thousand seventeen. He says it drug companies are getting away with murder with murder. Farm Form Has a lot of lobbies lobbyists a lot of power from a podium at trump tower or trump. The president elect echoed the remarks of trump the candidate almost verbatim with the largest Bhairab drugs in the world and yet we don't bid properly we're going to start bidding save billions of dollars over that really sent shockwaves through the drug industry. In fact the stock prices for many drugs plummeted after he said that. But then Pharma saw some reassuring signs weeks later pharmaceutical CEOS and the head of Pharma met with trump in the White House and the president backed off and said that trying to give Medicare negotiating power would be tantamount to price fixing everyone's sort of head-spinning but former thanks. Okay well maybe. That was One little mistake that he made in the press conference and roll back to being friends again. Uh-huh and our power still exists. Power still exists. Thinking things were returning to normal. Pharma went back to lobbying the way it always had and trump meanwhile named a former drug company executive to run the Department of Health and Human Services. It seemed like Pharma was back on top but it was about to learn that things in Washington had actually changed the first tangible sign of farmers loss and influence came in the budget. Bill of two thousand eighteen congress and trump or trying to put together a budget for the entire government. A very small part of this was the budget for Medicare when it came to Medicare congressional leaders were seven billion dollars short so to plug the gap. Nancy Pelosi Chuck Schumer Paul Ryan and Mitch. Mcconnell came up with a solution they could all live with through a complicated change to Medicare payments they stick drug companies with the seven billion dollar bill. The reason that Republican leadership was willing to do. This wasn't just because of the rising public animosity toward drug companies. It also had to do with the way the drug lobby had treated its Republican allies during the obamacare fight. The problem was in order. For Pharma to support Obamacare they had to ditch Republicans. Essentially Republicans are fighting tooth and nail against Obamacare and. Here's one of their longtime allies. The pharmaceutical industry who they've worked hand in glove with for decades ditching them and going and running and supporting obamacare. So they felt betrayed yet. And also I I should say like I'm not sure if a Lotta people know this recalled run around and really bemoan what Pharma did back then. It was more of a quiet. Seething sort of thing and I was talking to Republicans a lot of them. Kinda quietly said you know. Remember back in two thousand nine. They felt like they were betrayed by an ally in a war and so when the time came for congressional leaders to solve their twenty eighteen budget dilemma. Republicans didn't have a problem forcing farm at a pick up the tab it fell the Republican majority leader Paul Ryan and his team to tell Pharma about the change but they never did. They felt the only way could get in. The middle was to not tell farm. They were worried that they tell Pharma. Farmers GonNa run this big lobbying campaign and crush it and the reason they thought that is because that's what farm had done for the last ten years on other proposals so they added to the bill. The bill becomes public farmer finds out about it and obviously very upset. Pharma wasn't just upset because Congress hit the change from them. They're upset because Congress had screwed up. The math drug companies weren't on the hook for seven billion dollars. They were on the hook for eleven billion dollars. The group appealed to its Republican allies for help. But they didn't get it because it wasn't just trump in Paul Ryan who Pharma couldn't count on anymore. It was a whole lot of Republicans in Congress. Taking aim at drug companies was becoming a bipartisan sport. I WanNA welcome and thank our witnesses in February two thousand nineteen the Senate. Finance Committee called a hearing with CEOS of the seven largest drug companies. The topic was high drug prices. The hero packed. Republicans and Democratic members are all their predictably Democrats. Senator Ron wyden ripped into the CEOS. Drug prices are astronomically high. Because that's where pharmaceutical companies and their investors want them. We sort of expect at a hearing like this. The Democrats are going to criticize industry. Ceo's surprising here represent the real pivot. Point was the number of Republicans who stood up and leveled similar criticism. Thank you MR chairman. I WANNA focus on Humira. John Cornyn was one of those. Republicans the senator from Texas press the CEO of the Drug Company abbvie about the company's blockbuster drug Humira why he wanted to know did Humira need one hundred thirty six different patents. So it was it. Is it your company's position that it should have an exclusive monopoly on that medication for thirty one years. It was really important moment. I thought because John Cornyn is a very conservative Republican from Texas. He's not the type of person who would go after a drug company for something like that. It sounded like something that Ron Widen. The Democratic chairman would go after a drug company for when Republicans do it. It really shows that your political influence is changing. Pharma sites one off anecdotes about certain drugs. Exploding in price as part of the reason why sentiment has changed both on and off Capitol Hill it also blames an advertising blitz by Industry opponents but whatever the cause farmers power seems to be waning. Does this mean that there may actually be Drug PRICES LEGISLATION. That could get past. It certainly seems more likely than ever that something's going to happen. I don't know exactly what's going to happen. But WHAT WE HAVE IS DONALD TRUMP? The president saying we need to do something on drug prices. We've Nancy Pelosi the House Democratic leader saying we need to do something. I'm drug prices. A bunch of big leaders are all saying we need to do something. The question is. Can they reach a compromise? Find a single solution To get something done. The Senate is trying in the months after the finance. Committee's hearing Republican Chuck Grassley Democrat. Ron WYDEN TEAMED UP ON A BILL TO REGULATE drug prices John Cornyn the conservative from Texas teamed up with the Democrat on a bill to prevent drug companies from using patents to lock in monopolies. So far far has failed to kill either bill. What do you take away from this story about? Pharma's apparent waning influence as someone who is covered lobbying and influence and big business in Washington. I sort of see what's happened to farm as a symptom of a broader shift in power in Washington and that is that the corporations which have had increasing powers since the early nineteen seventy s are suddenly on their heels companies and trade associations and industries used to have incredible power in Washington with the Republican Party but also the Democratic Party and could really do what they want. They took down environmental groups. They took down. Labor unions took down consumer groups now. Something's changing because of the rise in populism in the Republican party because the rise of populism in the Democrat Party big industries across the board have seen their influence wane. The oil industry's had problems. Big Tech we've seen. He's come under the gun. Pharma is now under the gun. We don't know what's going to happen in two or four years. This could be a temporary blip. This could be a little speed bump or visit a radical realignment.

Pharma DONALD TRUMP John Cornyn trump tower president Paul Ryan verizon Texas Congress Senator Ron wyden Drug Company Republican Party Washington Medicare Ceo Senate chairman obamacare
"pharma r" Discussed on The Journal.

The Journal.

07:42 min | 1 year ago

"pharma r" Discussed on The Journal.

"The lobbying group that for decades has represented drugmakers in Washington goes by an acronym P. H. R. N. A. Farmer yes. The pharmaceutical research and manufacturers of America which has been shortened for many many years to be Pharma and for Years Pharma the organization. We'll do the kind of clout in DC. That other industries could only dream about Barma has been a killer organization. People are afraid of them saying Washington you want to be there feared or respected they were respected and feared maybe their respective because they feared they had a reputation of going to lawmakers. And saying we need you to vote for us here or we're going to run campaign ads against you. Defeat you in your Congressional District Pharma. The budget to potentially unseat members of Congress and Congress. People knew it but just like Pharma could break politician's campaign could make it to. They had so much in fact that farmer would run ads for a member of Congress in their district and then after they won the election. Once there's nothing left at stake they often went back and ran ads thanking voters for voting for the member of Congress. Wow this is sort of add. Some Cherry on the top Pharma was able to exercise that power for years because it had two major things going for it money and friends in high places. The money came from the companies that farmer represents drugmakers like Eli Lilly and Pfizer. Pay Pharma annual dues to lobby for them on the hill. The friends came mostly from the Republican Party. And that's because they share the same ideological bent. Which is the government particularly the federal government. Should not get involved in the free market economy. So if you are Pharma your goal is to essentially just keep Republicans in your corner. Sort of a simple ideas. I get all of your allies in the Republican Party. Reach out to some Democrats and you're gonNA always have fifty one percent of the vote for decades. This strategy worked for Pharma for example in two thousand and three Republicans put forward a bill that would give seniors access to prescription drugs through Medicare for the first time for drugmakers. This was a huge opportunity. The government was about to start buying tons of drugs and the legislation stipulated that the government would have. To give up its negotiating. Power Medicare wouldn't directly negotiate with drug companies over drug prices because of that the vote was very contentious it dragged on and on as farmers. Republican allies tried to bring reluctant lawmakers on board in the super inside. Dc baseball world. It was actually an incredibly fascinating. Vote on the House floor. Off for Mister Dooley back in two thousand and three Tom. Delay of my remember him was in charge of this. Vote off. No on I for Mr Scott. Who Georgia votes in the House are normally fifteen minutes and fifty minutes. Bell goes off and everyone's votes are counted. Some boats recycle and they say who want her lost. This vote was held open for more than two hours. It was so close when so far down the movie consideration. I did thanks to your arm twisting. I'd suspend as to speak it. Took Republicans more than two hours to pass the bill? That's like a football game ending and waiting two hours while the game goes on with the clock stopped until the home team wins. The as are two twenty two naser to fifteen. The conference agree to objector. The most recent laid upon the table that day Pharma one big time. It was just a sign of their strength. I mean they got a huge huge new market. Medicare. There were not allowed to negotiate the prices. I mean there was like a double win for Pharma for Pharma. This wasn't just a win for drug companies bottom line but also for innovation the drug companies. Say That bigger profits means more money for research and development for new drugs Pharma dominated even when Democrats were in control. When obamacare came up for a vote in two thousand nine the lobby worked around. Its Republican allies made a deal with Democrats. Drug companies would support obamacare and eighty billion dollars to help fund it. If Democrats didn't mess with drug companies pricing that ended up being in my opinion. Incredibly savvy deal. It led to huge continuing prophets but while Pharma was dominating on the hill reputation among Americans especially when it came to drug prices was getting worse and worse. And no one embodies this problem better than a thirty something hedge fund manager named Martin Scroll. He's a CEO so despised that he's been labeled the most hated man in America. What IS PHARMACEUTICAL COMPANY? Raise the price of an AIDS drug around thirteen dollars a pill to seven hundred fifty dollars a pill overnight. In two thousand fifteen he became a symbol of corporate greed. His nickname Pharma Bro. Headlines like these fed a perception that drug companies were out for profit not patients wellbeing something that Pharma Disputes But at Twenty Nineteen poll would find that seventy two percent of Americans felt drug companies had too much power in Washington. Seventy nine percent would say that. Drug prices were unreasonable. In two thousand ten Americans paid about eight hundred dollars per year on average for prescription drugs by two thousand seventeen. That number had risen by about two hundred dollars to a little over a thousand dollars. That's a twenty five percent increase but for many people. It feels even worse than that. A lot of health. Insurance plans have created high deductible plans with a high deductible plan consumers pay more of the drug prices up front as it used to be a certain prescription drugs that you got from your doctor through your healthcare plan. You never paid for it all now. Under these higher deductible plans you pay them right away so there is a perception. That drug prices are really skyrocketing. This perception became a political issue in the two thousand sixteen presidential election both nominees Donald Trump and Hillary Clinton criticized drug prices. Clinton call drug companies price gougers and trump at a campaign rally in New Hampshire in two thousand sixteen. You know what's happening with the drugs right. Took aim at precisely. The thing Pharma had fought so hard for back in two thousand and three Medicare's inability to negotiate on drug prices. Because we're not allowed for some reason. I don't know what the reason is. I do know what the reason is but I don't know how they can sell it. We're not allowed to negotiate drug prices. Can you believe it so still when trump eventually won the presidency? Pharma was relieved even though trump had campaigned a bit complaining about drug prices correct. I think they thought that maybe that's just campaign rhetoric and at the end the day. He's a Republican. Remember at the time. Republicans were their friends. Republicans are people who believe fundamentally the government should not be involved in the private sector economy. I think Pharma hoped that trump was a traditional conservative Republican. But it wouldn't take long for Pharma to realize just how wrong they were. That's after the break..

Pharma Congressional District Pharma Years Pharma Medicare day Pharma Donald Trump Congress Republican Party Washington America P. H. R. N. A. Farmer Barma Eli Lilly obamacare baseball Pfizer AIDS Hillary Clinton
"pharma r" Discussed on a16z

a16z

10:18 min | 1 year ago

"pharma r" Discussed on a16z

"That's true but the reimbursement being first in class being having this huge Jumped in care that that is a real challenge amount and so what I would love to see especially in our founders is for them to work backwards and but work backwards not from through trials but work backwards from reimbursement and the way hey that that voss describes it I think is is absolutely true is a lot of people view reimbursement as a process to get to market access but reimbursement is really really just a proxy for value proposition. So what are the actual user stories. Who's GonNa actually value this? WHO's willing to pay? It's almost like a pricing study It's almost like a price discovery in the consumer Zuma world in this case it's it's you know the obviously the payers not direct beneficiary of the therapeutic but they they do bear the burden of the cost and so there. The great arbiter of saint is their true value proposition. And actually. That's why when you talk about moving away industry moving away from me too drugs. It was because me to drug arguably could not show a very significant -nificant marginal increase value proposition. And therefore you could be very difficult to justify. It increased premium price. That historically has been the big challenge on that note. I do you find it. Ironic a big part of your business is still generics so I mean what is that but a meat you drag like. How does that fit into the big picture You know if you look overall at Novartis Generics Genetics. You know from a sales standpoint in value standpoint is is a small portion of the company. But you'll get a volume standpoint. It's the biggest part of access and so really what a generics Are Generics business does is take when medicines go off patent you know we then produce them as scale we're the largest producer for example of penicillins in the world. I mean so we. We have a huge role to play in providing access to medicines around the world. I mean right now. Novartis reaches about a billion patients a year Through through are working in a lot of that is through our Sandoz generics unit. So if you break it down so you the seventy billion doses. That are Navarre drugs every year. How many of those seventy billion are generics Eric's roughly eighty percent? Is it standard that big pharmaceutical companies have their own manufacturing facilities. And do you see that changing anytime in the near future Gotcha. Most pharmaceutical companies have have their own own manufacturing. And there's different trends right now. I'm just a a pretty significant increase of use of Chinese and another producers from many elements of the manufacturing but still historically we've had our manufacturing facilities the biggest one we have right now is a shift to these advanced therapy platform. So we're having to do as as our volumes. Go down and kind of the old older Madison's that were produced in huge volumes and innovative medicines We're now building of cell and gene therapy production facilities around the world. So that's that's a shift where we're seeing you know you talk about. Nevada's becoming a medicines company using data the science and novel platforms. You're very specific about saying. Medicines are medicines and therapeutic synonyms in in the number artis mindset I would say yes. There's of course a grey zone era so you know what is a therapeutic. We would say you know. Medicines is our proxy for Therapeutics One example we launched in the US us a digital medicine. I mean with Pera Therapeutics. This is the first digital APP with an FDA label that's being used for opioid addiction and another psychiatric illnesses and it is literally an APP that has run clinical trials and has gotten an FDA approved label. So that's truly an example sample of of a therapeutic but I would put that within our world medicines to software as a drug your software as a drug most surprising indication that you would expect to see for digital therapeutic because I think most people assume that it's going to be around a behavioral health issues or addiction like with with the work. You've done with pair. Can you imagine moving beyond that from indication standpoint for digital therapeutic. I mean my my hope would be. We could develop one for obesity right that somehow that a digital therapeutic picked that could actually just move the needle a little bit more on obesity such a massive issue for society and it should be one where a behavioral intervention prevention on top of other interventions could actually move the needle and because so much of it is behavioral. I mean there's not a an example. That's non behavioral on your future curing sickle cell with with an APP against her on fertility. But one could argue. That's I mean the things that actually so you easing but like the modern medical sort of marvel's I think about like antibiotic like I was sick when I was in college and I had a super high fever. Got An antibiotic and like next few days. I'm fine MHM maybe without that I've been dead and so that's kind of magic lance not like after take antibiotics my life or whatever like that. I'm sure but you know the amazing thing about behavioral is that that's where you don't have this. I can't imagine that you have a molecule that cures depression you take that and then you're done or you take one when a couple of doses and then you're no longer longer have type two diabetes and behavioral really broad. It's it's depression smoking sensation. It's type two diabetes. It's even quite possibly Alzheimer's I don't know if you've seen like modern a lot of recent papers waiting and so these are actually the areas where you look at the biology of Alzheimer's disease. That's just a mess. You know so it could be that for these things where you you have a very clear target. I just have to hit the rise of the bacteria. And then we're done that's easy but there maybe actually the future of the heartache with molecule and all that is primarily April April interesting so basically almost arguing the question might be moot because all diseases behavioral some component of all the stuff that it's not the the the long molecular early right is is not behavioral. There's just infrastructure layer. That's being created now around in therapies. So as folks figure out manufacturing facturing as people think about delivery as people think about all of the various components of modular aspects. Do you think those are things that necessarily would be Owned by one company or these horizontal infrastructure layers that You know a third party Should develop and deploy across the industry. How do you think think this plays out in other words? Is there a startup that figures out a vis do they sort of supply av to the industry or do they go and develop their own gene therapy. It's a very timely question. We don't know the answer yet. I think right now in this Nascent phased that were in a we believe we need to disown it because because the launches are so important that we can't afford there to be a lot of experimentation and not being not really owning the supply chain we've done fifteen billion dollars of acquisitions just last last year in the space not not including all our internal work in each of these areas. So we've chosen to build out the infrastructure ourselves. I think as the technology matures chirs. We'll get more comfortable about which areas we would send out. I also think the entrepreneurial world will also figure out where they can play a role. I think that's still all being Figured out right now And I don't actually don't have a view yet. I don't know what's going to be the elements we must own. And what are the elements that we could afford to to give to other parties ladies in on that note. I'd love to hear from you more about how you figured out the build versus buy piece then because a big part of your work is focused on innovative medicines. When you made this argument that it takes ten years to build up a base even longer twenty thirty years and yet you're also acquiring the expertise for the very new cutting edge things which almost makes it seems like? You don't seem like you don't have to even bother building up that base. Why not just acquire it? So how'd you sorta navigate the build versus. Buy Part of this. I think when you want to enter very new areas Sometimes it's prudent to ask yourself to somebody. Somebody have this much more figured out than you do. If you take the example of gene therapy we acquired a company called vaccines though it really is I think the front leading edge gene therapy company now the scientists at Eveque Sis You know they've been working at this. Actually in their academic labs for for twenty I five years. I mean. They've been working on trying to hone how to use AV vectors to get to the neuro muscular system of children to address to address these issues. They've actually she figured out the manufacturing they built manufacturing site. We were working on on gene therapies ourselves in house but when we looked at that we said this is an opportunity to really accelerate what we're doing coming in so it made sense. I think to to go to go external. There's always that balance you know we are a company that's very focused internally on research we consistently Justin Lee Invest at the high end on internal are indeed simply because we believe that's the heart of the company. But I what I'm trying to keep asking people if there's somebody out there who's got it better thus let's just let's just go get that build off of it. I love that but there is classic. NIH noninvasive here syndromes. And when you have a strong internal. RND Culture it does compete with NIH a lot so the question it really begs is how you then with all these amazing acquisitions integrate them into the company and actually make sure the classic Chess Bro. Study of all these acquisitions being killed by the big company like how do you balance that piece. So I think there's two things I'd say one one is as a rnd. The person I have the ability to to really get in there and have the discussion directly with the scientists and argue why we need to actually go external and really evaluate the case With with hopefully objective is the other thing we've decided to do at least with these very new tech three new technology platforms leave them as independent units and really let them Grow up independent from the BIG RND and manufacturing. Because I think for that concern it. It's very it makes sense to let them build up in really incubate these new technologies get them all sorted out and then we can ask the question. What's the right set-up down the line right right that is what the classic studies show that Adam the way to do the success? I did find it very fascinating. 'cause I wasn't aware of that. You have a scientific background. It reminds me of the idea that we had around. CTO lead you know. Really having technical people at the helm. So I am curious about your view I mean besides being able to talk to the internal scientists like. How's IT affected your own career trajectory at Novartis so far given the company's hard innovative Madison and most of my background has been developed in drug development and really developing vaccines and in developing Various medicines I think it gives me a really good.

Novartis FDA NIH Zuma voss Nevada obesity Therapeutics One Pera Therapeutics Alzheimer Adam Madison producer US Eric CTO
"pharma r" Discussed on a16z

a16z

10:59 min | 1 year ago

"pharma r" Discussed on a16z

"We have one of our reruns which was recorded during the J. P. Morgan Healthcare Conference last year ear where the a six and Z bio team had a lot and has a lot going on this year as well and it's with Bosnia symon the CEO of Novartis One of the largest healthcare and pharmaceutical missile companies in the world in terms of volume. They're the largest producer of medicines with seventy billion doses a year across a wide range of therapeutic areas from cancer a cardiovascular disease and more joining me to interview him are as six general partners or hey conde and Bj Sunday from the Ason Z.. Bio Team and we cover the latest trends and therapeutics including the journey in Chemistry and medicine from large molecules and antibodies and proteins to small molecules and other a new modalities with RNA. And now moving more into the cell and gene engineered world we also cover when science becomes engineering. And what does that mean at an industry mystery and a big company innovation level and then we touch on topics such as clinical trials healthcare go to market shifts and talent in the landscape and.

J. P. Morgan Healthcare Confer CEO of Novartis One producer conde Bosnia
"pharma r" Discussed on WBZ NewsRadio 1030

WBZ NewsRadio 1030

01:58 min | 1 year ago

"pharma r" Discussed on WBZ NewsRadio 1030

"Pharma the maker of oxycontin some say this action is long overdue because you want to treat patients that we want to help people heal to walk into a building every day after a family that is doing the opposite it's been really hard to do in a statement top says it is clear that the Sackler name with its link to the current health crisis runs counter to the school's mission Sackler family attorney says the name removal is based on unproven allegations adding we will be seeking to have this improper decision reversed and are currently reviewing all options available to us the Sackler family brought in fifteen million dollars to the university spanning over nearly forty year relationship well it's something that hasn't happened in many years and your report says prescription drug prices have gone up I'm Gary non prices are lower but not by March one percent still the decline in prescription drug prices is the first in forty five years according to the federal centers for Medicare and Medicaid services the main reason for the down take his reliance on generics prices are slightly higher from any brand name drugs the drop does not include medications administered in hospitals and doctors offices overall spending on prescription drugs rose two and a half percent last year Gary none CBS news for the very first time the state's marijuana dispensaries are being linked to possible vaping related lung injury six of the probable vaping related long illness patients got their products from a license state marijuana dispensary according to new data from state health officials the findings would run contrary to studies that have found the large majority of illnesses come from black market vape oil with additives like vitamin a acetate health officials specified the products reportedly used by the patients they've interviewed so far but they didn't give information on the legal dispensaries because of this some cannabis advocates are saying the state should publish that information the governor Baker's ban on vaping products is set to end next Wednesday the cannabis control commission has a ban on T. H. C..

attorney Gary marijuana Baker cannabis control commission Sackler Medicare CBS cannabis fifteen million dollars forty five years one percent forty year